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Chapter I 
 
Progress toward the Total Synthesis of Marineosin A 
 
1.1. Introduction 
 Natural products have been important in traditional medicine, the development of chemical 
methodology, and the pharmaceutical industry for hundreds of years.  The synthesis of natural 
products has played a significant role in the growth of organic chemistry, and natural products are 
the inspiration for approximately half of the approved drugs in the United States.1  The Lindsley 
lab was attracted to the total synthesis of marineosin A for these reasons.  Herein describes the 
synthetic efforts put forth to synthesize this interesting natural product. 
 
1.2. Marineosins A and B 
The marineosins (Figure 1.1) were discovered in 2008 by Fenical and co-workers from a 
marine-derived Streptomyces-related actinomycete.2  These natural products have a novel structure 
containing two pyrrole functionalities, a 12-membered macrocycle, and a spiroiminal center.  
Marineosins A and B differ only at two stereocenters, the spirocenter (C8) and the methoxy 
substituent (C7).  In the HCT-116 human colon tumor cell line, marineosin A displayed an IC50 = 
0.5 µM while marineosin B was much weaker at 46 µM.  When further tested in the National 
Cancer Institute (NCI) 60 cell line panel, marineosin A showed considerable cytotoxic selectivity 
against melanoma and leukemia without affecting other cell lines.2   
 
 
Figure 1.1.  Chemical structures of the marineosins. 
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The marineosins belong to the same family of natural products as the prodigiosin alkaloids 
(Figure 1.2).  The prodigiosins are a large family of molecules consisting of a 
pyrrolylpyrromethene core with varying alkyl substituents at C13.3  Prodigiosin family members 
exhibit a wide range of biological activities including antibacterial, antimalarial, anticancer and, 
most significant in the clinic, immunosuppressive activity.3  There has been much interest in the 
prodigiosins, and many total syntheses of these compounds have been reported. 
 
 
Figure 1.2.  Representative members of the prodigiosin family. 
 
1.3. Literature Review 
 
1.3.1. Proposed Biosyntheses 
In his initial report, Fenical proposed a biosynthesis of the marineosins from a known 
prodigiosin intermediate (Scheme 1.1).2  This route encompasses the condensation of 4-methoxy-
2,2’-bipyrrole-5-carbaldehyde (MBC, 1.6), precursor of the prodigiosins, with pyrrole 1.7.  The 
product of this reaction could undergo an inverse-electron-demand hetero-Diels–Alder cyclization 
to form spiroiminal 1.9.  This Diels–Alder would ultimately give rise to the diastereomers that are 
marineosins A and B, as cyclization can occur from above or below the enone plane of 1.8.  Further 
reduction would provide the natural products. 
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Scheme 1.1.  Fenical’s proposed biosynthesis of the marineosins.2 
 
 An attempt at a biomimetic total synthesis of marineosin A based on Fenical’s proposed 
biosynthesis was reported from our lab in 2010.4  Chemistry was developed to synthesize both 
precursors 1.11 and 1.7 in four steps each (Scheme 1.2).  The aldehyde and enone smoothly 
underwent condensation to form the inverse-electron-demand hetero-Diels–Alder substrate (1.8).  
Unfortunately, all conditions attempted failed to affect the desired cyclization to spiroiminal 1.9.  
Molecular modeling revealed that 1.8 is unlikely to reach a favorable conformation (key atoms 
being within three Angstroms of each other) for the Diels–Alder reaction to occur.  This study 
concluded that laboratory conditions would not be able to prove this biosynthetic proposal.4  
Several intermolecular Diels–Alder conditions were attempted but also proved unsuccessful, 
suggesting that the dienophile is insufficient as a coupling partner.  This is likely due to the removal 
of electron density through the highly conjugated system. 
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Scheme 1.2.  Attempted biomimetic synthesis of marineosin A.4 
 
 Snider envisioned a different biosynthetic pathway to the marineosins.  He did not favor 
the six-electron oxidation followed by four-electron reduction that Fenical’s route required.5  
Snider proposed a biosynthesis starting from undecylprodigiosin (1.4, Figure 1.2) that only 
required one enzyme to perform a single two-electron oxidation.  Using his proposal as a guide, 
Snider began work on a model system to test this strategy for the synthesis of the spiroiminal core 
of the marineosins (Scheme 1.3).   
 Vinylmagnesium bromide addition into lactone 1.13 followed by triethyl silyl (TES) 
protection afforded enone 1.14.  Addition of 2-(trimethylsilyl)ethoxymethyl (SEM) protected 
pyrrolyl oxime 1.15 proceeded in 73% yield to form isoxazoline 1.16.  Incorporation of an 
unprotected pyrrole lead to degradation and byproducts in subsequent reactions, so the group 
resorted to the SEM-protected pyrrole.   Isoxazoline 1.16 underwent hydrogenolysis with Raney 
nickel followed by bis-methylation of the alcohols.  Hydrochloric acid (HCl) was utilized to 
hydrolyze the silyl ether, affect the loss of methanol, and close the spiroiminal.  This step gave a 
mixture of three diastereomers after two weeks of equilibration time.  Deprotection with tetra-
butylammonium fluoride (TBAF) yielded the three diastereomers shown.   
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Scheme 1.3.  Snider’s route to the spiroiminal core of the marineosins.5 
 
 The fused macrocyclic ring of the marineosins forces the methyl group into an axial 
position, but in these smaller systems, the methyl group resides in an equatorial position.  Of the 
three diastereomers, 1.20 has the same spirocenter and methoxy configuration as marineosin B; 
however, none have the absolute stereochemistry exhibited by marineosin A.   
 In his dissertation in 2012, S. Salem of the Reynolds lab sequenced the gene cluster 
responsible for the biosynthesis of the marineosins.6  He reported that the enzyme MarG oxidizes 
hydroxyundecylprodigiosin (1.22) and that the following macrocyclization and spiroiminal 
formation give dehydromarineosin A (1.23, Scheme 1.4).  MarG is a RedG homologue, an enzyme 
known to catalyze the production of the prodigiosins.  Salem also reports that the enzyme MarA 
catalyzes the final reduction to yield marineosin A.6   
 
 
Scheme 1.4.  Reynolds/Salem’s biosynthesis of marineosin A.6 
 
6 
 
 Snider wanted to test Salem’s final reduction of the enol ether to marineosin A chemically.7  
Treatment of 1.24, an intermediate in his previous model system, with hydrofluoric acid (HF) in 
tetrahydrofuran (THF) gave 3-methoxypyrrole 1.25 (Scheme 1.5).  Reaction of 1.25 with 
manganese dioxide (MnO2) in acetone gave two separable spiroiminals, 1.26 and 1.27.  
Hydrogenation of these two compounds with palladium on barium sulfate (Pd/BaSO4) provided 
four diastereomers, thus mimicking the reduction claimed by Salem to be the last step in the 
biosynthesis of marineosin.   
 
Scheme 1.5.  Snider’s chemical proof of Salem’s biosynthetic reduction.7 
 
 Spiroiminal 1.30 was formed in 40% yield, and although it has the same relative 
stereochemistry as marineosin A, it exhibits a very different conformation.7  Whereas marineosin 
A’s macrocyclic ring locks the tetrahydropyran ring into a formation with the nitrogen and methyl 
in axial positions, 1.30 prefers the nitrogen and methyl groups to be equatorial due to steric 
interactions.  Snider’s next goal was to prepare a more substituted model system that would exhibit 
the same conformation as marineosin A. 
 
1.3.2. Snider’s Advanced Model System and Progress toward the Total Synthesis of 
Marineosin A 
In order to synthesize a more substituted model system with hopes of preparing a 
compound with the same conformation as marineosin A, Snider added phenyl and propyl groups 
to his initial model system.7  From parasorbic acid (1.32), the iodolactone was formed and 
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subsequent Buchwald–Hartwig coupling yielded phenyl lactone 1.33 (Scheme 1.6).  Conjugate 
addition with allylmagnesium bromide followed by hydrogenation provided trisubstituted lactone 
1.34.  Transformation to the Weinreb amide with N,O-dimethylhydroxylamine was followed by 
protection of the secondary alcohol and addition of vinyl Grignard to yield enone 1.35.  The next 
four steps, developed in their previous model system, gave two diastereomers, 1.37 and 1.38.  The 
isomer matching the stereochemistry of marineosin A (1.38) was the major product in a 7:1 ratio 
and was shown to adopt the same conformation as marineosin A.7   
 
Scheme 1.6.  Snider’s more functionalized model system.7 
 
 After completing the synthesis of spiroiminal 1.38, Snider’s focus turned to the pyrrole-
containing macrocycle of marineosin A (Scheme 1.7).7  Aldehyde 1.39 was subjected to 1,2-
addition followed by Ley oxidation8 and subsequent reduction with sodium borohydride to give 
pyrrole 1.40.  This pyrrole was then t-butoxycarbonyl (Boc) protected and transformed to boronic 
acid 1.41 with lithium 2,2,6,6-tetramethylpiperidide (LTMP) and trimethyl borate.  Suzuki 
coupling with iodolactone 1.42 afforded pyrrolyl lactone 1.43.  Conjugate addition of allyl 
Grignard gave a 5:4 mixture of the undesired cis isomer (1.44) and Boc-migrated compound (1.45) 
in 56% yield.  Treatment of this mixture with trimethylsilyl (TMS) triflate removed the Boc groups 
and afforded the desired trans isomer (1.46).  Ring closing metathesis (RCM) with 30 mol% 
Grubbs II at reflux for 16 hours yielded the macrocycle in 41% yield, and hydrogenation gave 
saturated ring system 1.47.   
8 
 
Scheme 1.7.  Snider’s synthesis of the macrocyclic pyrrole.7 
 
 An X-ray crystal structure of macrocycle 1.47 confirmed the stereocenter conformation 
and indicated that the lactone adopts a boat conformation with the pyrrole nitrogen perpendicular 
to the macrocycle (Figure 1.3).7 
 
 
Figure 1.3.  X-ray crystal structure of macrocycle 1.47.7 
 
 In attempt to complete the total synthesis of marineosin A, Snider combined his model 
system syntheses.7  From pyrrole macrocycle 1.47, the lactone was opened via Weinreb amide 
formation, and the alcohol was TES protected (Scheme 1.8).  Enone 1.48 was synthesized by 1,2-
addition of vinyl lithium into the amide.  Cycloaddition with SEM-protected pyrrole 1.15 gave 
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isoxazoline 1.49, and hydrogenolysis gave imine 1.50.  Only three steps remained from 
intermediate 1.50 to marineosin A.  Unfortunately, a variety of methylation conditions failed to 
methylate the diol.  These hydroxyl groups appear to be more hindered than in the model systems, 
and hemi-iminal 1.50 decomposed under all conditions tested.  In addition, Snider and co-workers 
tried to form the spiroiminal before methylation but only decomposition was seen.  Hemi-iminal 
1.50 is the furthest reported intermediate Snider achieved using this method; however, one can 
assume that Snider’s efforts to complete the total synthesis are still underway. 
 
 
Scheme 1.8.  Snider’s efforts toward the total synthesis of marineosin A.7 
 
1.4. Progress toward the Total Synthesis of Marineosin A 
 The Lindsley lab recently reported our progress toward the total synthesis of marineosin 
A.9,10  This work includes the completion of the first 21 steps of a 29 step proposal en route to the 
natural product, an advanced model system to test late reactions of the synthesis, and a smaller 
model system to test the installation of pyrrole in the last step. 
 
1.4.1. Synthesis toward Marineosin A 
Several of the Lindsley lab’s first attempts to synthesize marineosin A failed due to early 
installation of the pyrrole rings.  In light of this, we imagined a retrosynthetic route that involved 
late stage installation of both pyrrole units.10  As shown in Scheme 1.9, the last step will be pyrrole 
addition into the lactam.  The spirocenter will be formed by acid-mediated cyclization.  Ring 
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closing metathesis and Paal–Knorr pyrrole synthesis will yield the macrocyclic pyrrole.  Diketone 
1.53 will be formed via Stetter reaction.  A regioselective epoxide opening will set the 
stereochemistry of the methoxy group.  A conjugate addition and aldol addition will set two 
stereocenters via Evan’s oxazolidinone, which leads us to the starting materials: chiral epoxide 
1.59, vinylmagnesium bromide, and Evan’s auxiliary phosphonate 1.58.   
 
Scheme 1.9.  Retrosynthetic analysis of marineosin A. 
 
 Forward synthesis began with the opening of (S)-propylene oxide via copper-promoted 
Grignard addition followed by protection of the resulting alcohol as a tert-butyldiphenylsilyl 
(TBDPS) ether (Scheme 1.10).10  Ozonolysis converted terminal olefin 1.62 to aldehyde 1.63 in 
84% yield.  To synthesize the required Horner–Wadsworth–Emmons (HWE) phosphonate 1.58, 
(R)-oxazolidinone 1.60 was acylated with bromoacetyl bromide to give 1.61 which then underwent 
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the Arbuzov reaction with triethyl phosphite.  Phosphonate 1.58 underwent HWE olefination with 
aldehyde 1.63 to afford the acyloxazolidinone (1.56) in 75% yield.   
 
Scheme 1.10.  Synthesis of acyloxazolidinone 1.56. 
 
 The above synthesis was a substantial improvement over the original route to 
oxazolidinone 1.56 (Scheme 1.11).  Initially, Grubbs II catalyzed cross metathesis between olefin 
1.62 and methyl acrylate.  Hydrolysis followed by addition of oxazolidinone 1.60 provided 
acyloxazolidinone 1.56.  In addition to removing one linear step and increasing overall yield, the 
new route reduced reaction time by three days and reduced cost by avoiding the use of Grubbs II 
in an early step of the total synthesis.   
 
 
Scheme 1.11.  Original route to acyloxazolidinone 1.56. 
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 Conjugate addition with allylmagnesium bromide and copper bromide proceeded through 
a chelated transition state to set one of the marineosin A stereocenters and provide oxazolidinone 
1.68 (Scheme 1.12).11  The necessary aldehyde for the aldol addition was synthesized from cis-
butene-1,4-diol.  Mono-para-methoxybenzyl (PMB) protection followed by allylic oxidation with 
manganese dioxide (MnO2) afforded aldehyde 1.57.  This compound was used in the Crimmins’ 
aldol reaction with titanium(IV) chloride to provide syn adduct 1.55.12  The Evan’s auxiliary was 
hydrolyzed with lithium borohydride to give the free primary alcohol which was transformed to 
the triisopropyl silyl (TIPS) ether (1.70).  Being important that the auxiliary removal be kept below 
0 °C, the mixture was separated into smaller reaction vessels and set up in icy salt water.  When 
the reaction was run at 0 °C, yields were only 33-36%. 
 
Scheme 1.12.  Synthesis of intermediate 1.70. 
 
 Oxirane 1.71 was formed via hydroxyl-directed vanadyl acetoacetate (VO(acac)2) 
epoxidation in 95% yield (Scheme 1.13).13  The secondary alcohol was benzyl protected, and the 
PMB group was reductively removed with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to 
provide alcohol 1.73.  Red-Al selectively opened the epoxide to 1,3-diol 1.74.14  The primary 
alcohol was protected as a pivalate ester, and the secondary alcohol was methylated to provide key 
intermediate 1.54. 
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Scheme 1.13.  Synthesis of intermediate 1.54. 
 
 From intermediate 1.54, the TIPS group was removed with boron trifluoride diethyl 
etherate (BF3∙OEt2), and the subsequent alcohol was oxidized to aldehyde 1.76 under Parikh–
Doering conditions15 (Scheme 1.14).  Addition into the aldehyde with vinylmagnesium bromide 
followed by oxidation provided enone 1.77.  This oxidation was originally performed with MnO2 
(62% yield), but the yield was increased (91%) and reaction time decreased using Dess–Martin 
periodinane16 (DMP).  A Stetter reaction17 with 6-heptenal (1.78) gave key 1,4-dione 1.53.  RCM 
with Grubbs I afforded a 1:1 mixture of the cis and trans olefins, which were carried on together.  
Finally, Paal–Knorr pyrrole synthesis18,19 was completed in five hours thermally.  The reaction 
time was improved to 20 minutes under microwave conditions to provide macrocyclic pyrrole 
1.80.  This is our most advanced intermediate in the total synthesis of marineosin A, attained in 21 
steps and 0.93% yield from (S)-propylene oxide. 
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Scheme 1.14.  Synthesis of our most advanced intermediate, pyrrole 1.80. 
 
 The initial conditions and yield for the RCM to macrocycle 1.79 proved problematic, 
calling for an investigation of reaction conditions (Table 1.1).  The use of Grubbs I in toluene 
(PhMe) and 1,2-dichloroethane ((CH2Cl)2) showed no improvement despite their ability to reach 
higher temperatures.  Alkylidene Grubbs I (1.82)20 and catalyst 1.8321 were both claimed to be 
ideal for closing 12- to 14-membered rings, but neither led to reaction completion.  Grubbs II and 
Hoveyda–Grubbs II showed complete conversion but with the same high catalyst loadings as 
Grubbs I.  Use of the molybdenum Schrock catalyst (1.86) did not progress the reaction.  Finally, 
microwave conditions were used to lower the catalyst loading, but the necessary high dilution, and 
thus low throughput, was not ideal for this reaction.  After this study, it was decided to continue 
performing this RCM with Grubbs’ first generation catalyst. 
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Table 1.1.  Results of various RCM conditions by TLC. 
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1.4.2. Substituted Model System 
 In order to save advanced material and test the late synthetic steps, a model system was 
developed from key intermediate 1.54 (Scheme 1.15).10  The pivalate ester was reductively 
removed with diisobutylaluminum hydride (DIBAL-H), and the resulting alcohol was oxidized 
with Parikh–Doering15 then Pinnick22 conditions to carboxylic acid 1.88.  Coupling with 
ammonium chloride (NH4Cl) provided the amide
23 which then underwent hydrogenolysis of the 
benzyl protecting group and hydrogenation of the olefin.  Ley oxidation transformed the alcohol 
to ketone 1.90,8 and cyclization was achieved with 0.01 M HCl in 86% yield.   
 
 
Scheme 1.15.  Synthesis of model spiroaminal 1.91. 
 
 1D and 2D NMR experiments were used to confirm the conformation of the stereocenters 
of spiroaminal 1.91 (Figure 1.4).  This model system represents marineosin A with the same 
absolute stereochemistry at all stereocenters.  The relative stereochemistry was determined by the 
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methyl group of the pyran ring, which was set by (S)-propylene oxide at the beginning of the 
synthesis.   
 
 
Figure 1.4.  NMR correlations of 1.91. 
 
1.4.3. Late Stage Pyrrole Installation 
In order to complete marineosin A, our synthesis calls for pyrrole installation onto a lactam 
as the last step.  To test conditions for this reaction, another model system was synthesized 
(inspired by Huang et al.24) with fewer substituents on the pyran ring.9  
First, THF was opened with aqueous hydrobromic acid (HBr) followed by hydroxyl group 
protection with tetrahydropyran (THP) (Scheme 1.16).  The resulting THP ether (1.94) was stirred 
with magnesium to form Grignard reagent 1.95.  The maleimide fragment (1.98) was prepared 
from a known condensation of (R)-hydroxysuccinic acid and PMB amine.25  Silver oxide mediated 
alkylation with iodomethane gave maleimide 1.98. 
 
Scheme 1.16.  Synthesis of coupling partners, 1.95 and 1.98. 
 
 Grignard addition of 1.95 into maleimide 1.98 proceeded in 80% yield to give tertiary 
alcohol 1.99 (Scheme 1.17).  Treatment with para-toluenesulfonic acid (p-TsOH) cleaved the THP 
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ether and generated an iminium salt that was regioselectively attacked by the hydroxyl group to 
give spiroaminal 1.101.  The PMB group was then removed with ceric ammonium nitrate (CAN), 
providing the desired spiroaminal (1.102) to test pyrrole installation conditions. 
 
Scheme 1.17.  Synthesis of spiroaminal 1.102 and nOe correlations of 1.101. 
 
 NMR experiments showed that, in comparison to marineosin A, lactam 1.101 possesses 
the same stereochemistry at the methoxy substituent but has the opposite stereochemistry at the 
spirocenter (Scheme 1.17).  The spirocenter likely does not take on the desired configuration due 
to the lack of substitution on the pyran ring, which does not favor the marineosin A conformation.  
Although the stereochemistry is not the same as marineosin A, this model system was still valuable 
as a substrate to test final reaction conditions. 
 Compound 1.102 was tested under many reaction conditions to install pyrrole onto the 
spirolactam (Scheme 1.18).  Vilsmeier-type chemistry using phosphoryl chloride26 as well as 
treatment with acid and pyrrole failed to provide 1.105.  Likewise, transformation of the carbonyl 
into the triflate followed by Suzuki coupling to 2-pyrrole boronic acid failed under many attempted 
conditions, including various metal sources, bases, solvents, and temperatures.   
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Scheme 1.18.  Failed methods of installing pyrrole. 
 
Based on the precedent set by Balenkova, the reaction shown in Scheme 1.19 was 
attempted.27  This method generates an iminium triflate salt in situ, and pyrrole acts as an 
intercepting nucleophile.  Various conditions were tested with differing equivalents of reagents; 
the best result yielded 36% 1.105 in 15 minutes with 1.0 equivalent triflic anhydride and 5.0 
equivalents pyrrole.  nOe studies of adduct 1.105 (Scheme 1.19) revealed no equilibration of the 
spirocenter with installation of pyrrole, even after two weeks in CDCl3. 
 
 
Scheme 1.19.  (a) Conditions for pyrrole addition. (b) nOe correlations. 
 
Repetition of this reaction sequence starting with (S)-hydroxysuccinic acid afforded a 
model system reminiscent of marineosin B in 9% overall yield (Scheme 1.20).  Both of these 
model systems were then tested in a HCT-116 human colon carcinoma cytotoxicity assay to 
ascertain if they contained the minimal pharmacophore of the marineosins’ activity.  Both were 
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determined to be inactive, suggesting that either the larger construct and/or stereochemical 
conformation are important for biological activity.9   
 
 
Scheme 1.20.  Synthesis of the model system representing marineosin B. 
 
Shortly after this synthesis was reported, Shi and co-workers published a very similar 
model system and pyrrole installation.28  Using 2.0 equivalents triflic anhydride in neat distilled 
pyrrole, they were able to yield 91% of spiroiminal 1.20 (Scheme 1.21).  Their model system 
contains the marineosins’ methyl substituent on the pyran ring, similar to Snider’s first model 
system.  Three diastereomers were obtained from this route: 1.20, 1.19 (representing marineosin 
B), and 1.110; however, Shi was not able to synthesize the marineosin A-like diastereomer, 1.21, 
using this method.   
 
 
Scheme 1.21.  Shi’s pyrrole addition with the isomers obtained in his study (1.20, 1.19, and 
1.110) and the one not obtained (1.21). 
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Upon reading this paper, we attempted our reported conditions with distilled pyrrole and 
increased the yield to 80% (Table 1.2).  When Shi’s exact conditions were tested on our substrate, 
a 71% yield was obtained.  With these results, we feel confident that this procedure will provide 
marineosin A in the last step of our synthesis. 
 
Table 1.2.  Yield of pyrrole installation under various conditions. 
 
 
1.4.4. Synthesis to Complete Marineosin A 
 Based on the two model systems that have been completed for marineosin A, we are 
confident in the proposed final reactions toward the total synthesis of the natural product.  All of 
the reactions have been tested on substrates similar to those shown in Scheme 1.22.  From our 
most advanced intermediate, 1.80, DIBAL-H will remove the pivalate ester.  Parikh–Doering and 
Pinnick oxidations followed by EDC coupling will provide primary amide 1.112.  Hydrogenolysis 
and Ley oxidation will afford ketone 1.52.  Acid-mediated deprotection and cyclization will give 
spirolactam 1.51.  Finally, pyrrole installation via triflate displacement will yield marineosin A. 
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Scheme 1.22.  Synthesis of marineosin A from pyrrole 1.80 based on model system syntheses. 
 
1.5. Conclusions 
 While there have been many successful efforts to synthesize prodiginine alkaloids, 
marineosin A has yet to succumb to total synthesis.  Our lab has completed a 21-step synthesis to 
an advanced macrocyclic pyrrole intermediate en route to marineosin A.  This intermediate 
contains most of the carbon backbone, lacking only the final pyrrole, and four of the five 
stereocenters of marineosin A.  In addition, we have completed two model systems that have 
allowed us to explore chemistry to form the spirocenter and install the final pyrrole ring.  Through 
the study of these two model systems, we have laid the groundwork for the completion of the total 
synthesis of marineosin A. 
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1.6. Experimental Methods 
 All reagents and solvents were commercial grade and purified prior to use when necessary. 
Analytical thin layer chromatography (TLC) was performed on Sorbent Technologies HL 0.25 
mm silica gel plates with UV indicator. Visualization was accomplished by irradiation under a 254 
nm UV lamp and/or the use of an iodine chamber or potassium permanganate stain. 
Chromatography on silica gel was performed using Silica Gel 60 (230-400 mesh) from Sorbent 
Technologies.  1H and 13C NMR spectra were recorded on a Bruker DRX-400 (400 and 100 MHz, 
respectively) NMR instrument. Chemical shifts are reported in ppm from the solvent resonance as 
an internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, m = multiplet, bs = broad singlet), coupling constant (Hz), and number of 
protons.  Optical rotations were measured on a JASCO P-2000 digital polarimeter at room 
temperature. Concentration (c) in g/100 mL and solvent are given in parentheses.  A Micromass 
Q-Tof API-US mass spectrometer was used to acquire high resolution mass spectrometry (HRMS) 
data. The value Δ is the error in the measurement (in ppm) given by the equation Δ = [(ME – MT)/ 
MT] × 106, where ME is the experimental mass and MT is the theoretical mass. The HRMS results 
were obtained with ES as the ion source and leucine enkephalin as the reference.  
 
 
1.62 
(S)-tert-butyl(pent-4-en-2-yloxy)diphenylsilane (1.62). Cuprous iodide (1.64 g, 8.61 mmol) was 
suspended in anhydrous tetrahydrofuran (17.5 mL) the resulting solution was cooled to -20 °C 
with vigorous stirring. Vinylmagnesium bromide (1.0 M in THF, 100 mL) was cannulated under 
a positive stream of argon into the stirring cuprous iodide over 20 min. The resulting black solution 
was stirred for 30 min before a solution of (S)-propylene oxide 1.59 (3.02 g, 43.04 mmol) in 
anhydrous tetrahydrofuran (5.5 mL) was added dropwise. The reaction mixture was stirred for 20 
h at -20 °C. At this time, the reaction was quenched by slow addition of saturated aqueous 
ammonium chloride and warmed to room temperature. The mixture was extracted with diethyl 
ether, dried over sodium sulfate, and filtered through celite. The organic layer was carefully 
concentrated under reduced pressure to avoid evaporation of the volatile homoallylic alcohol. The 
remaining solvent was removed by gently blowing air across the surface of the crude reaction 
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mixture. After 20 min, the remaining yellow oil was carried on to the next step without further 
purification. The crude homoallylic alcohol was suspended in dichloromethane (108 mL) and to 
this imidazole (5.86 g, 86.1 mmol) was added followed by tert-butyldiphenylchlorosilane (16.5 
mL, 64.6 mmol) at room temperature. The reaction was stirred for 2 h at room temperature and 
quenched by the addition of water when complete. The mixture was extracted with 
dichloromethane, dried over sodium sulfate, and concentrated in vacuo to give a thick, yellow oil. 
The crude oil was purified by chromatography (0-10% ethyl acetate in hexanes) and condensed 
under reduced pressure to give silyl ether 1.62 as a clear yellow oil (11.3 g, 81% over 2 steps).  
1H NMR (CDCl3, 400 MHz)  (ppm): 1.14 (s, 9H), 1.145 (d, J = 3.0 Hz, 3H), 2.22-2.33 (m, 2H), 
3.98 (sext, J = 6.0 Hz, 1H), 5.01-5.06 (m, 2H), 5.84 (dddd, J = 17.0, 11.2, 10.4, 7.6 Hz, 1H), 7.41-
7.49 (m, 6H), 7.75-7.78 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm): 19.4, 23.0, 27.2, 44.1, 
69.3, 116.9, 127.6, 127.6, 129.6, 129.6, 134.6, 134.9, 135.2, 136.0, 136.0. HRMS: C21H28ONaSi, 
Calculated [M+Na]+: 347.1807, Found [M+Na]+: 347.1804.  [α]D20 = -15.7 (c = 1.0, CHCl3). 
 
 
1.63 
(S)-3-((tert-butyldiphenylsilyl)oxy)butanal (1.63).  Olefin 1.62 (8.15 g, 25.1 mmol) was 
suspended in dichloromethane (251 mL) and cooled to -78 °C.  Ozone was bubbled in until the 
solution turned blue (about 45 min).  Triphenylphosphine (7.90 g, 30.1 mmol) was then added and 
the flask was purged with argon.  This was stirred at room temperature under an atmosphere of 
argon for 1 h.  The solution was then concentrated under vacuum and purified by column 
chromatography (0-5% ethyl acetate in hexanes) to give colorless oil 1.63 (6.90 g, 84%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.12 (s, 9H), 1.24 (d, J = 6.4 Hz, 3H), 2.53-2.65 (m, 2H), 
4.43 (sext, J = 6.0 Hz, 2H), 7.42-7.48 (m, 6H), 7.75 (dd, J = 8.0, 1.6 Hz, 4H), 9.79 (t, J = 6.4, 1H). 
13C NMR (CDCl3, 100 MHz) δ (ppm): 19.1, 23.8, 26.9, 52.7, 65.6, 127.6, 127.7, 129.7, 129.8, 
133.5, 134.0, 135.8, 201.7. HRMS: C20H26O2NaSi, Calculated [M+Na]
+: 349.1600, Found 
[M+Na]+: 349.1601.  Spectral data matches that recorded by S. Barluenga, et al.29 
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1.61 
(R)-4-benzyl-3-(2-bromoacetyl)oxazolidin-2-one (1.61).  (R)-4-benzyl-2-oxazolidinone 1.60 
(12.5 g, 70.5 mmol) was dissolved in anhydrous tetrahydrofuran (282 mL) and cooled to -78 °C 
before adding n-butyl lithium (2.5 M in hexanes, 71.9 mmol) dropwise.  This solution was stirred 
for 10 min at -78 °C.  Bromoacetyl bromide (6.27 mL, 71.9 mmol) was added neat and this solution 
was stirred for 10 min at -78 °C then 1.5 h at room temperature.  When the reaction was complete 
by TLC, it was quenched with saturated aqueous ammonium chloride, extracted with ethyl acetate, 
dried over sodium sulfate, and condensed in vacuo.  The resulting oil was purified by column 
chromatography (0-50% ethyl acetate in hexanes) to give the product as a yellow oil (18.6 g, 88%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.81 (dd, J = 13.2, 9.6 Hz, 1H), 3.33 (dd, J = 13.6, 3.2 Hz, 
1H), 4.21-4.30 (m, 2H), 4.54 (d, J = 3.2 Hz, 2H), 4.67-4.73 (m, 1H), 7.20-7.37 (m, 5H). 13C NMR 
(CDCl3, 100 MHz) δ (ppm): 28.2, 37.4, 55.4, 66.6, 127.5, 129.0, 129.4, 134.7, 152.9, 165.9. 
HRMS: C12H13NO3Br, Calculated [M+H]
+: 298.0079, Found [M+H]+: 298.0081. [α]D20 = -34.5 (c 
= 0.5, CHCl3).  Spectral data matches that recorded by D.A. Evans and A. Weber.
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1.58 
(R)-diethyl (2-(4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethyl)phosphonate (1.58). 
Acyloxazolidinone 1.61 (1.49 g, 5.00 mmol) was suspended neat in triethylphosphite (1.74 mL, 
10.0 mmol).  A reflux condenser was attached to the flask and the solution was heated at 100 °C 
for 2 h.  This solution was loaded directly onto a column for chromatography (0-75% ethyl acetate 
in hexanes).  This yielded the pure product as a yellow oil (1.45 g, 82%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.35 (t, J = 7.2, 6H), 2.75 (dd, J = 13.2, 10 Hz, 1H), 3.35 
(dd, J = 13.2, 3.2 Hz, 1H), 3.80 (dq, J = 30.8, 19.7 Hz, 2H), 4.10-4.24 (m, 6H), 4.68-4.74 (m, 1H), 
7.21-7.35 (m, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 16.2, 16.3, 33.6, 34.9, 37.6, 55.4, 62.7, 
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65.9, 127.3, 128.9, 129.4, 135.0, 153.3, 165.0. HRMS: C16H23NO6P, Calculated [M+H]
+: 
356.1263, Found [M+H]+: 356.1264. [α]D20 = -35.3 (c = 1.0, CHCl3). 
 
 
1.56 
(R)-4-benzyl-3-((S,E)-5-((tert-butyldiphenylsilyl)oxy)hex-2-enoyl)oxazolidin-2-one (1.56).  
Phosphonate 1.58 (10.8 g, 30.4 mmol) was suspended in anhydrous tetrahydrofuran (204 mL) and 
cooled to 0 °C.  Sodium hydride (60% dispersion in mineral oil, 29.2 mmol) was added and the 
resulting solution was stirred for 15 min at 0 °C then 45 min at room temperature.  This solution 
was cooled to -78 °C before adding aldehyde 1.63 (7.95 g, 24.3 mmol) in anhydrous 
tetrahydrofuran (98.0 mL).  This was stirred at -78 °C for 10 min then allowed to warm to 0 °C.  
At 2 h, the reaction was complete by TLC and the solution was quenched with pH 7 phosphate 
buffer, extracted with ethyl acetate, dried over sodium sulfate, and concentrated in vacuo.  The 
resulting oil was purified by column chromatography (0-25% ethyl acetate in hexanes; 100% ethyl 
acetate to recover excess phosphonate 1.58) to give the pale yellow oil of acyloxazolidinone 1.56 
(9.60 g, 75%).   
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.07 (s, 9H), 1.13 (d, J = 6.2 Hz, 3H), 2.43 (q, J = 5.6 Hz, 
2H), 2.78 (dd, J = 13.0, 9.6 Hz, 1H), 3.33 (dd, J = 13.5, 3.2 Hz, 1H), 4.03 (sext, J = 5.9 Hz, 1H), 
4.19-4.23 (m, 2H), 4.73 (ddd, J = 13.2, 7.2, 3.4 Hz, 1H), 7.19-7.43 (m, 14 H), 7.68-7.70 (m, 4H). 
13C NMR (CDCl3, 100 MHz) δ (ppm): 19.4, 23.4, 26.5, 27.1, 38.0, 42.7, 55.4, 66.2, 68.7, 122.5, 
127.4, 127.7, 127.8, 129.1, 129.6, 129.7, 129.8, 134.1, 134.5, 135.5, 136.0, 136.0, 148.2, 153.5, 
164.8. HRMS: C32H37NO4NaSi, Calculated [M+Na]
+: 550.2390, Found [M+Na]+: 550.2393. 
[α]D20 = -52.8 (c = 1.0, CHCl3). 
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1.68 
(R)-4-benzyl-3-((S)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)hex-5-enoyl) oxazolidin-2-
one (1.68). Recrystallized CuBr-S(CH3)2 complex (23.3 g, 113 mmol) (Procedure for 
recrystallization: 50 g CuBr-S(CH3)2 was dissolved in 250 mL dimethyl sulfide at 50 °C before 
dripping in 1 L hexanes and filtering off solvent) was suspended in dimethyl sulfide and 
tetrahydrofuran (1:2 v/v, 226 mL) and cooled to -78 °C. This solution was cannulated into a -78 
°C solution of allylmagnesium bromide (1.0 M in diethyl ether, 90.6 mmol). The resulting thick, 
black solution was vigorously stirred for 1 h at -78 °C and then acyloxazolidinone 1.56 (11.9 g, 
22.6 mmol) in anhydrous tetrahydrofuran (75 mL) was slowly added over 20 min. The reaction 
mixture was stirred for an additional 1.5 h at -78 °C and then quenched with saturated aqueous 
ammonium chloride and warmed to room temperature. The black mixture was extracted with 
diethyl ether, dried over sodium sulfate, the solvent volume reduced to approximately 200 mL by 
rotary evaporation, and the resulting solid/oil mixture filtered through a celite plug with liberal 
diethyl ether washes. The solution was condensed in vacuo to give a turquoise oil that was purified 
by column chromatography (0-20% ethyl acetate in hexanes) to provide the desired conjugate 
addition adduct 1.68 as a clear, colorless oil (10.4 g, 81%) and a single diastereomer by 1H NMR 
(>20:1).  
1H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 9H), 1.12 (d, J = 6.1 Hz, 3H), 1.41 (quin, J = 7.0 
Hz, 1H), 1.60 (quin, J = 7.0 Hz, 1H), 1.91-2.03 (m, 2H), 2.22 (quin, J = 6.1 Hz, 1H), 2.63 (dd, J 
= 17.9, 5.8 Hz, 1H), 2.68 (dd, J = 13.0, 10.0 Hz, 1H), 2.87 (dd, J = 17.9, 7.2 Hz, 1H), 3.28 (dd, J 
= 13.4, 3.3 Hz, 1H), 3.92 (sext, J = 6.2 Hz, 1H), 4.10-4.20 (m, 3H), 4.65 (ddd, J = 13.4, 6.9, 3.2 
Hz, 1H), 4.92-4.91 (m, 2H), 5.62 (dddd, J = 16.7, 10.2, 9.0, 7.2 Hz, 1H), 7.20-7.43 (m, 11H), 7.66-
7.70 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm): 19.3, 23.6, 26.5, 27.2, 30.4, 38.1, 38.4, 39.5, 
43.8, 55.3, 66.2, 67.7, 77.4, 116.9, 127.5, 127.6, 127.7, 129.0, 129.1, 129.6, 129.6, 134.4, 134.9, 
135.5, 136.1, 136.1, 136.3, 153.5, 172.5. HRMS: C35H43NO4NaSi, Calculated [M+Na]
+: 
592.2859, Found [M+Na]+: 592.2854. [α]D20 = -41.0 (c = 0.5, CHCl3). 
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1.67 
(Z)-4-((4-methoxybenzyl)oxy)but-2-en-1-ol (1.67). Sodium hydride (4.77 g, 119 mmol, 60% 
dispersion in mineral oil) was suspended in anhydrous tetrahydrofuran (227 mL). The solution was 
cooled to 0 °C and 1,4-cis-buten-1-ol 1.66 (10.0 g, 114 mmol) was added dropwise. The resulting 
mixture was stirred for 30 min at 0 °C at which time p-methoxybenzyl chloride (16.9 mL, 125 
mmol) was added dropwise followed by addition of tert-butyl ammonium iodide (4.19 g, 11.4 
mmol). The mixture was warmed to room temperature and stirred for 12 h. The reaction was 
quenched by dropwise addition of saturated aqueous ammonium chloride solution. The resulting 
mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under 
reduced pressure. The oil was purified by column chromatography (0-60% ethyl acetate in 
hexanes) to give PMB ether 1.67 (13.8 g, 68%).  
1H NMR (CDCl3, 400 MHz)  (ppm): 3.80 (s, 3H), 4.05 (d, J = 6.0 Hz, 2H), 4.15 (d, J = 6.3 Hz, 
2H), 4.45 (s, 2H), 5.76 (dm, J = 35.0 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5, 1H). 13C 
NMR (CDCl3, 100 MHz)  (ppm): 55.2, 58.6, 65.3, 72.0, 113.8, 128.2, 129.4, 129.9, 132.3, 159.2. 
HRMS: C12H16O3Na, Calculated [M+Na]
+: 231.0997, Found [M+Na]+: 231.0995.  Spectral data 
matches that recorded by D. Könning, et al.31 
 
 
1.57 
(E)-4-((4-methoxybenzyl)oxy)but-2-enal (1.57). PMB ether 1.67 (13.8 g, 76.7 mmol) was 
suspended in dichloromethane (153 mL). Manganese dioxide (80.0 g, 920 mmol) was added and 
the resulting heterogeneous mixture was vigorously stirred for 48 h at room temperature. The 
mixture was filtered through celite and condensed in vacuo to give a pale yellow oil. The oil was 
purified by column chromatography (0-40% ethyl acetate in hexanes) to provide aldehyde 1.57 as 
a clear, colorless oil (5.00 g, 36%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 3.83 (s, 3H), 4.28 (dd, J = 4.1, 1.9 Hz, 2H), 4.54 (s, 2H), 
6.41 (ddt, J = 15.9, 8.0, 1.9 Hz, 1H), 6.86 (dt, J = 15.9, 4.1 Hz, 1H), 6.92 (d, J = 8.4 Hz, 2H), 7.29 
(d, J = 8.2 Hz, 2H), 9.60 (d, J = 7.7 Hz, 1H). 13C NMR (CDCl3, 100 MHz)  (ppm): 55.4, 68.4, 
72.8, 114.1, 129.5, 129.6, 131.9, 153.4, 159.6, 193.5. HRMS: C12H14O3Na, Calculated [M+Na]
+: 
29 
 
229.0841, Found [M+Na]+: 229.0841.  Spectral data matches that recorded by D. Könning, et al.31 
 
 
1.55 
(R)-4-benzyl-3-((2R,3S,E)-2-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-3-
hydroxy-6-((4-methoxybenzyl)oxy)hex-4-enoyl)oxazolidin-2-one (1.55). Acyloxazolidinone 
1.68 (8.81 g, 15.5 mmol) was suspended in anhydrous dichloromethane (154 mL) and cooled to 0 
°C.   Titanium tetrachloride (1.78 mL, 16.2 mmol) was added dropwise and the resulting yellow 
solution was stirred for 15 min. At 0 °C, diisopropylethylamine (2.96 mL, 17.0 mmol) was slowly 
added and the dark red mixture was stirred for 40 min while maintaining the temperature at 0 °C. 
N-methylpyrrolidinone (1.49 mL, 15.5 mmol) was added dropwise and the solution stirred for 10 
min. Aldehyde 1.57 (3.35 g, 16.2 mmol) in anhydrous dichloromethane (65.0 mL) was added 
dropwise at 0 °C. After addition was complete, the solution was stirred for 1.5 h at 0 °C, quenched 
with saturated aqueous ammonium chloride, and warmed to room temperature. The dark orange 
solution was extracted with dichloromethane and filtered through a celite plug. The solvent was 
removed under reduced pressure at room temperature, and the resulting orange oil was purified by 
column chromatography (0-45% ethyl acetate in hexanes)  to provide the syn aldol adduct 1.55 
(5.24 g, 65% brsm, 10:1 dr). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.05 (s, 9H), 1.07 (d, J = 6.0 Hz, 3H), 1.49-1.56 (m, 1H), 
1.61-1.67 (m, 1H), 1.80-1.86 (m, 2H), 2.01-2.09 (m, 1H), 2.11-2.18 (m, 1H), 2.48 (dd, J = 13.0, 
10.7 Hz, 1H), 3.30 (dd, J = 13.2, 3.2 Hz  1H), 3.79 (s, 3H), 3.97-4.04 (m, 5H), 4.27 (t, J = 7.5 Hz, 
1H), 4.43 (s, 3H), 4.46-4.50 (m, 1H), 4.60-4.66 (m, 1H), 4.83 (d, J = 17.1 Hz, 1H), 4.90 (d, J = 
10.0 Hz, 1H), 5.55 (dddd, J = 16.8, 9.9, 7.2, 5.0 Hz, 1H), 5.81-5.83 (m, 2H), 6.85 (d, J = 8.6 Hz, 
2H), 7.17-7.43 (m, 14H), 7.66-7.71 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm): 19.3, 23.1, 
27.1, 34.7, 35.2, 38.4, 40.9, 50.6, 55.4, 55.7, 66.0, 67.6, 69.8, 72.0, 113.9, 117.1, 127.4, 127.6, 
127.7, 129.1, 129.4, 129.5, 129.6, 129.7, 130.2, 130.4, 131.9, 134.5, 134.8, 135.5, 136.05, 153.8, 
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159.3, 173.4. HRMS: C47H58NO7Si Calculated [M+H]
+: 776.3983, Found [M+H]+: 776.3982. 
[α]D20 = -22.1 (c = 1.2, CHCl3). 
 
 
1.70 
(4S,5S,6S,E)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-1-((4-methoxybenzyl)oxy-
5(((triisopropylsilyl)oxy)methyl)nona-2,8-dien-4-ol (1.70). Aldol adduct 1.55 (6.11 g, 7.87 
mmol) was suspended in anhydrous tetrahydrofuran (78.7 mL) and cooled to -5 °C. Anhydrous 
methanol (1.28 mL, 31.4 mmol) was added followed by lithium borohydride slowly (15.7 mL, 2.0 
M in tetrahydrofuran), and the reaction was stirred for 6 h until complete by TLC. Water was added 
dropwise to quench and the solution was extracted with ethyl acetate, dried over sodium sulfate, 
condensed in vacuo, and purified by column chromatography (0-50% ethyl acetate in hexanes) to 
give diol 1.69 as a clear, colorless oil  (2.09 g, 44%). This diol (3.34 g, 5.54 mmol) was suspended 
in anhydrous dichloromethane (55.0 mL) and imidazole (1.88 g, 27.7 mmol) was added followed 
by dropwise addition of chlorodiisopropylsilane (2.37 mL, 11.1 mmol) at room temperature. After 
1 h, an additional 27.7 mmol of imidazole and 11.1 mmol of chlorodiisopropylsilane were added. 
After 1 h, 1.15 mL of chlorodiisopropylsilane was added and the solution was stirred for an 
additional 1 h and quenched by addition of water after the reaction was determined to be complete 
by TLC. The mixture was extracted with dichloromethane, dried over sodium sulfate, condensed 
in vacuo, and purified by column chromatography (0-30% ethyl acetate in hexanes) to give 
triisopropylsilyl ether 1.70 as  clear, colorless oil (3.47 g, 82%).  
1H NMR (CDCl3, 400 MHz)  (ppm): 1.04 (s, 33H), 1.44-1.49 (m, 1H), 1.55-1.63 (m, 1H), 1.71 
(quin, J = 7.2 Hz, 1H), 1.87-1.93 (m, 1H), 2.03-2.09 (m, 1H), 3.45 (d, J = 7.2 Hz, 1H), 3.76 (d, J 
= 6.8 Hz, 2H), 3.80 (s, 3H), 3.90 (sext, J = 6.2 Hz, 1H), 4.00 (d, J = 3.0 Hz, 2H), 4.25-4.29 (m, 
1H), 4.45 (s, 2H), 4.84-4.91 (m, 2H), 5.49 (dddd, J = 16.9, 9.8, 7.2, 7.0 Hz, 1H), 5.84-5.85 (m, 
2H), 6.87 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 7.34-7.43 (m, 6H), 7.66-7.69 (m, 4H). 13C 
NMR (CDCl3, 100 MHz)  (ppm): 11.9, 18.1, 19.3, 23.4, 27.2, 33.3, 35.1, 41.9, 47.5, 55.4, 63.4, 
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68.2, 70.1, 71.8, 73.9, 113.9, 116.4, 127.6, 127.7, 128.5, 129.4, 129.6, 129.7, 130.6, 133.35, 134.5, 
134.9, 136.0, 136.7, 159.3. HRMS: C46H71O5Si2, Calculated [M+H]
+: 759.4840, Found [M+H]+: 
759.4836. [α]D20 = -16.2 (c = 1.0, CHCl3). 
 
 
1.71 
(1R,2S,3S)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-1-((2S,3S)-3-(((4-
methoxybenzyl)oxy)methyl)oxiran-2-yl)-2-(((triisopropylsilyl)oxy)methyl)hex-5-en-1-ol 
(1.71). Triisopropylsilyl ether 1.70 (1.89 g, 2.45 mmol) was suspended in anhydrous 
dichloromethane (10.0 mL) and the solution was cooled to 0 °C.  Vanadyl acetylacetonate (31.0 
mg, 0.123 mmol) was added followed by dropwise addition of tert-butyl hydrogen peroxide (1.34 
mL, ~5.5 M in decane). The resulting dark red solution was stirred at 0 °C for 4 h and an additional 
5 mol% vanadyl acetylacetonate was added.  Once the reaction had proceeded to completion the 
crude reaction mixture was transferred directly to a silica column that had been equilibrated with 
1% triethylamine in hexanes and was purified using 0-25% ethyl acetate in hexanes to give oxirane 
1.71 as a clear, colorless oil and a single diastereomer by 1H NMR (1.79 g, 94%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.03 (s, 33H), 1.46 (quin, J = 6.4 Hz, 1H), 1.64 (quin, 7.2 
Hz, 1H), 1.72 (quin, J = 7.2 Hz, 1H), 1.86-1.89 (m, 2H), 2.13-2.18 (m, 1H), 2.85 (d, J = 4.7 Hz, 
1H), 3.08 (dd, J = 4.4, 2.3 Hz, 1H), 3.20 (dt, J = 6.1, 2.2 Hz, 1H), 3.38 (dd, J = 11.6, 6.2 Hz, 1H), 
3.76-3.86 (m, 4H), 3.80 (s, 3H), 3.92 (sext,  J = 6.4 Hz, 1H), 4.50 (dd, J = 25.6, 11.6 Hz, 2H), 
4.86-4.90 (m, 2H), 5.53 (dddd, J = 19.6, 9.8, 9.2, 7.4 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 7.27 (d, J 
= 8.6 Hz, 2H), 7.33-7.43 (m, 6H), 7.67-7.69 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm): 11.9, 
18.1, 19.3, 23.3, 27.2, 32.9, 35.4, 42.1, 47.0, 54.5, 55.4, 56.5, 62.7, 68.3, 69.9, 70.6, 73.0, 113.9, 
116.2, 127.5, 127.6, 129.5, 129.6, 130.1, 134.5, 134.9, 136.0, 137.3, 159.4. HRMS: C46H71O6Si2, 
Calculated [M+H]+: 775.4789, Found [M+H]+: 775.4785. [α]D20 = -8.9 (c = 1.0, CHCl3). 
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1.73 
((2S,3S)-3-((1R,2S,3S)-1-(benzyloxy)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-2-
(((triisopropylsilyl)oxy)methyl)hex-5-en-1-yl)oxiran-2-yl)methanol (1.73). Sodium hydride 
(60% dispersion in mineral oil, 361 mg, 9.03 mmol) was suspended in anhydrous tetrahydrofuran 
(45.0 mL) and the solution was cooled to 0 °C.  A solution of oxirane 1.71 (3.50 g, 4.52 mmol) in 
tetrahydrofuran (15.0 mL) was slowly added to the sodium hydride solution, followed by 
immediate addition of benzyl bromide (2.14 mL, 18.1 mmol) and tert-butylammonium iodide (333 
mg, 0.903 mmol). The solution was warmed to room temperature and stirred for 2 h. An additional 
361 mg sodium hydride and 2.14 mL benzyl bromide were added at room temperature. The 
reaction was stirred 2 h until confirmed to be finished by LCMS. The reaction was quenched by 
the addition of saturated aqueous ammonium chloride, extracted with ethyl acetate, dried over 
sodium sulfate, and condensed in vacuo to give a yellow oil that was purified by column 
chromatography (0-15% ethyl acetate in hexanes) to provide benzyl ether (1.72) as a clear, 
colorless oil (3.10 g, 79%).  This benzyl ether (1.90 g, 2.20 mmol) was suspended in a mixture of 
dichloromethane and pH 7 phosphate buffer (7:1 v/v, 44 mL). The solution was cooled to 0 °C and 
2,3-dichloro-5,6-dicyanobenzoquinone (598 mg, 2.64 mmol) was added.  The resulting biphasic 
solution was vigorously stirred for 12 h at 0 °C. The reaction was quenched by addition of saturated 
aqueous sodium bicarbonate, extracted with dichloromethane, dried over sodium sulfate, and 
condensed in vacuo to provide a yellow residue that was purified by column chromatography (0-
20% ethyl acetate in hexanes) to provide alcohol 1.73 as a clear, colorless oil (1.19 g, 73%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.02-1.05 (m, 33H), 1.44-1.53 (m, 2H), 1.62-1.67 (m, 1H), 
1.68-1.75 (m, 1H), 1.84-1.91 (m, 1H), 1.94-2.01 (m, 1H), 2.21-2.27 (m, 1H), 3.05 (dd, J = 4.88, 
2.2 Hz, 1H), 3.11 (quin, J = 2.3 Hz, 1H), 3.44 (ddd, J = 12.7, 7.4, 5.0 Hz, 1H), 3.63 (t, J = 5.1 Hz, 
1H), 3.68-3.82 (m, 3H), 3.95 (sext, J = 6.2 Hz, 1H), 4.52 (dd, J = 55.6, 11.8 Hz, 2H), 4.83-4.87 
(m, 2H), 5.54 (dddd, J = 15.3, 10.2, 7.2, 6.2 Hz, 1H), 7.25-7.42 (m, 11H), 7.68 (d, J = 7.2 Hz, 4H). 
13C NMR (CDCl3, 100 MHz)  (ppm): 12.1, 18.2, 19.3, 23.5, 27.1, 32.9, 35.9, 42.8, 47.5, 56.7, 
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56.8, 60.7, 61.8, 68.6, 73.8, 77.4, 115.7, 127.5, 127.6, 127.6, 128.4, 129.6, 129.6, 134.8, 135.0, 
136.0, 138.3, 139.1.  HRMS: C45H69O5Si2, Calculated [M+H]
+: 745.4684, Found [M+H]+: 
745.4681. [α]D20 = -6.5 (c = 0.5, CHCl3). 
 
 
1.74 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-
(((triisopropylsilyl)oxy)methyl)non-8-ene-1,3-diol (1.74). Alcohol 1.73 (1.74 g, 2.34 mmol) was 
suspended in anhydrous tetrahydrofuran (156 mL) and cooled to 0 °C. Sodium bis(2-
methoxyethoxy)aluminum hydride (65 wt% in toluene, 4.35 mL, 14.0 mmol) was added dropwise 
and the resulting solution was warmed to room temperature and stirred for 5 h, until the reaction 
neared completion and the undesired free primary alcohol resulting from TIPS deprotection began 
to form. At this time, saturated sodium potassium tartrate solution was added dropwise and the 
resulting cloudy emulsion was diluted with 50 mL of ethyl acetate and stirred for 30 min until the 
organic layer became clear. The product was extracted with ethyl acetate, dried over sodium 
sulfate, and condensed in vacuo to give a thick, clear oil. This oil was purified by column 
chromatography (0-30% ethyl acetate in hexanes) to provide the desired 1,3-diol 1.74 (1.10 g, 79% 
based on recovered starting material) as the only product (1H NMR >20:1 1,3 diol:1,2 diol). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.04-1.09 (m, 33H), 1.49-1.56 (m, 1H), 1.60-1.67 (m, 1H), 
1.74-1.82 (m, 3H), 1.89-1.95 (m, 1H), 2.04-2.12 (m, 1H), 2.16-2.21 (m, 1H), 2.94 (bs, 1H), 3.51 
(t, J = 6.0 Hz, 1H), 3.74-3.89 (m, 5H), 3.95-4.02 (m, 2H), 4.52 (s, 2H), 4.83-4.87 (m, 2H), 5.37-
5.47 (m, 1H), 7.26-7.44 (m, 11H), 7.68-7.71 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm): 12.0, 
18.1, 18.2, 19.3, 23.2, 27.1, 32.0, 34.8, 34.9, 42.3, 46.2, 60.9, 62.6, 68.7, 73.4, 74.6, 82.3, 116.5, 
127.6, 127.6, 127.7, 127.8, 128.5, 129.6, 129.6, 134.7, 135.0, 136.0, 136.8, 138.5.  HRMS: C45H71-
O5Si2, Calculated [M+H]
+: 747.4840, Found [M+H]+: 747.4843. [α]D20 = -20.0 (c = 1.0, CHCl3). 
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1.54 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-methoxy-5-
(((triisopropylsilyl)oxy)methyl)non-8-en-1-yl pivalate (1.54). Diol 1.74 (978 mg, 1.31 mmol) 
was suspended in anhydrous dichloromethane (65.4 mL).  Pyridine was added (1.05 mL, 13.1 
mmol) followed by addition of pivaloyl chloride (0.970 mL, 7.85 mmol) at room temperature, and 
the resulting solution was stirred for 2 h. The reaction was quenched by addition of saturated 
aqueous sodium bicarbonate, extracted with dichloromethane, dried over sodium sulfate, and 
condensed in vacuo to give a cloudy, white residue. This residue was purified by column 
chromatography (0-20% ethyl acetate in hexanes) to give the pivalate ester as a clear, colorless oil 
(850 mg, 78%). This pivalate ester (1.10 g, 1.41 mmol) was suspended in anhydrous 
dichloromethane (132 mL). To this, 1,8-bis(dimethylamino) naphthalene (1.70 g, 7.94 mmol) was 
added followed by addition of trimethyloxonium tetrafluoroborate (0.979 g, 6.62 mmol) at room 
temperature. The resulting solution was stirred at room temperature for 1.5 h until TLC indicated 
that the reaction was complete. The reaction was quenched by addition of saturated aqueous 
sodium bicarbonate, extracted with dichloromethane, dried over sodium sulfate, and condensed in 
vacuo to give a pale yellow residue. This residue was purified by flash chromatography (0-15% 
ethyl acetate in hexanes) to provide the desired methyl ether 1.54 as a clear, colorless oil (812 mg, 
73%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.00-1.07 (m, 33H), 1.19 (s, 9H), 1.45 (quin, J = 6.8 Hz, 
1H), 1.61-1.74 (m, 3H), 1.82-1.94 (m, 1H), 1.95-2.05 (m, 1H), 2.07-2.13 (m, 1H), 2.14-2.21(m, 
1H), 3.36 (s, 3H), 3.55 (d, J = 9.2 Hz, 1H), 3.60-3.68 (m, 2H), 3.80 (dd, J = 8.4, 1.7 Hz, 1H), 3.92 
(sext, J = 6.1 Hz, 1H), 4.11-4.17 (m, 1H), 4.21-4.27 (m, 1H), 4.70 (dd, J = 143.5, 11.4 Hz, 2H), 
4.78-4.82 (m, 2H), 5.42-5.52 (m, 1H) 7.22-7.41 (m, 11H), 7.65-7.67 (m, 4H). 13C NMR (CDCl3, 
100 MHz)  (ppm): 12.1, 18.3, 19.3, 23.4, 27.1, 27.4, 28.9, 33.0, 35.8, 38.8, 43.1, 46.2, 57.5, 61.9, 
62.5, 68.7, 74.0, 77.4, 78.4, 81.4, 115.4, 127.3, 127.5, 127.6, 127.8, 128.3, 129.5, 129.5, 134.7, 
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135.2, 136.0, 138.8, 139.2, 178.7.  HRMS: C51H80O6NaSi2, Calculated [M+Na]
+: 867.5391, Found 
[M+Na]+: 867.5389. [α]D20 = -7.5 (c = 1.0, CHCl3). 
 
 
1.75 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-
(hydroxymethyl)-3-methoxynon-8-en-1-yl pivalate (1.75). Methyl ether 1.54 (808 mg, 0.956 
mmol) was suspended in anhydrous dichloromethane (95.6 mL). Boron trifluoride diethyl etherate 
(46.5%, 0.507 mL, 1.91 mmol) was added dropwise at room temperature and the resulting mixture 
was stirred for 30 min until TLC showed that the reaction had reached completion. The reaction 
was quenched by addition of saturated aqueous sodium bicarbonate, extracted with 
dichloromethane, dried over sodium sulfate, and condensed in vacuo to give a clear oil. This oil 
was purified by flash chromatography (0-30% ethyl acetate in hexanes) to give the free primary 
alcohol 1.75 as a clear, colorless oil (565 mg, 86%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (s, 9H), 1.03 (d, J = 6.2 Hz, 3H), 1.20 (s, 9H), 1.46 
(quin, J = 6.6 Hz, 1H), 1.61-1.71 (m, 2H), 1.77-1.83 (m, 1H), 1.85 (t,  J = 5.3 Hz, 1H), 1.88-1.97 
(m, 1H), 1.99-2.05 (m, 1H), 2.06-2.12 (m, 1H), 3.39 (s, 3H), 3.51-3.65 (m, 3H), 3.74 (dd, J = 8.3, 
2.2 Hz, 1H), 3.93 (sext, J = 6.1 Hz, 1H), 4.20 (dd, J = 7.7, 5.5 Hz, 1H), 4.63 (dd, J = 115.4, 11.6 
Hz, 2H), 4.84-4.87 (m, 2H), 5.40-5.50 (m, 1H), 7.25-7.42 (m, 11H), 7.65-7.68 (m, 4H). 13C NMR 
(CDCl3, 100 MHz)  (ppm): 19.3, 23.2, 27.2, 27.4, 29.6, 33.1, 35.5, 38.9, 42.3, 46.0, 58.0, 60.8, 
62.0, 68.8, 73.7, 77.4, 79.0, 80.6, 116.1, 127.5, 127.6, 127.6, 128.0, 128.4, 129.6, 129.6, 134.6, 
134.9, 136.0, 137.9, 138.7, 178.7.  HRMS: C42H60O6NaSi, Calculated [M+Na]
+: 711.4057, Found 
[M+Na]+: 711.4055. [α]D20 = -9.7 (c = 0.2, CHCl3). 
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1.76 
(3R,4R,5R,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-5-formyl-3-
methoxynon-8-en-1-yl pivalate (1.76). Alcohol 1.75 (324 mg, 0.470 mmol) was suspended in 
dichloromethane/dimethylsulfoxide (4:1 v/v, 23.5 mL) and cooled to 0 °C. Triethylamine (0.660 
mL, 4.70 mmol) was added followed by addition of sulfur trioxide pyridine complex (300 mg, 
1.88 mmol). The resulting solution was allowed to warm to room temperature and stirred for 6 h. 
Additional portions of triethylamine (0.660 mL, 4.70 mmol) and sulfur trioxide pyridine complex 
(300 mg, 1.88 mmol) were added. The reaction was stirred for 10 h and then quenched by addition 
of water, extracted with dichloromethane, dried over sodium sulfate, and condensed in vacuo to 
give a pale yellow oil. This oil was purified by flash chromatography (0-15% ethyl acetate in 
hexanes) to provide aldehyde 1.76 as a clear, colorless oil (220 mg, 68%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 0.99 (s, 9H), 1.01 (d, J = 6.4 Hz, 3H), 1.18 (s, 9H), 1.50 
(ddd, J = 14.4, 7.6, 5.6 Hz, 1H), 1.68-1.78 (m, 2H), 1.80-1.85 (m, 1H), 2.26 (dm,  J  = 14.0 Hz, 
1H), 2.34-2.41 (m, 1H), 2.71 (dt,  J  = 9.8, 2.8 Hz, 1H), 3.19-3.23 (m, 1H), 3.36 (s, 3H), 3.99 (sext, 
J = 6.0 Hz, 1H), 4.11-4.20 (m, 3H), 4.66 (dd, J = 123.6, 11.6 Hz, 2H), 4.90-4.97 (m, 2H), 5.53 
(ddt,  J = 23.0, 9.8, 7.2 Hz, 1H), 7.27-7.41 (m, 6H), 7.64-7.67 (m, 4H), 9.62 (d,  J  = 2.4 Hz, 1H). 
13C NMR (CDCl3, 100 MHz)  (ppm): 19.3, 23.4, 27.2, 27.4, 29.4, 32.9, 35.6, 38.9, 41.4, 56.0, 
58.0, 61.5, 68.1, 74.0, 75.5, 81.3, 117.1, 127.6, 127.7, 128.0, 128.5, 129.6, 129.8, 134.3, 134.9, 
136.1, 136.1, 137.0, 138.4, 178.6, 202.9. HRMS: C42H58O6NaSi, Calculated [M+Na]
+: 709.3900, 
Found [M+Na]+: 709.3896. [α]D20 = +3.7 (c = 0.4, CHCl3). 
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1.77 
(3R,4R,5R,6S)-5-acryloyl-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-
methoxynon-8-en-1-yl pivalate (1.77). Aldehyde 1.76 (200 mg, 0.291 mmol) was suspended in 
anhydrous tetrahydrofuran (29.0 mL). The solution was cooled to -78 °C and vinylmagnesium 
bromide (1.0 M in tetrahydrofuran, 0.582 mmol, 0.580 mL) was added dropwise. The resulting 
mixture was stirred at -78 °C for 1 h until TLC indicated the reaction had reached completion. 
Saturated aqueous ammonium chloride was added, and the mixture was extracted with ethyl 
acetate, dried over sodium sulfate, condensed in vacuo, and purified by flash chromatography (0-
25% ethyl acetate in hexanes) to provide the allylic alcohol as a clear, colorless oil.  The resultant 
alcohol (230 mg, 0.322 mmol) was suspended in anhydrous dichloromethane (32.0 mL).  Dess–
Martin Periodinane (205 mg, 0.483 mmol) was added and the cloudy white reaction was stirred 
for 45 minutes at room temperature.  It was then quenched with saturated aqueous sodium 
bicarbonate, extracted with dichloromethane, dried over sodium sulfate, and concentrated in 
vacuo.  The oil was purified by flash chromatography (0-20% ethyl acetate in hexanes) to provide 
enone 1.77 as a clear, colorless oil (208 mg, 68% over 2 steps). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 0.95 (d, J = 6.2 Hz, 3H), 0.98 (s, 9H), 1.15 (s, 9H), 1.17-
1.21 (m, 1H), 1.43 (dt, J = 13.7, 6.5 Hz, 1H), 1.62 (quin, J = 7.0 Hz, 2H), 1.69-1.78 (m, 1H), 1.80-
1.89 (m, 1H), 2.01-2.05 (m, 1H), 2.29 (quin, J = 6.9 Hz, 1H), 3.04 (d,  J = 10.0 Hz, 1H), 3.09 (dd, 
J = 10.6, 2.8 Hz, 1H), 3.35 (s, 3H), 3.85 (sext,  J = 6.2 Hz, 1H), 4.10-4.18 (m, 2H), 4.23 (d, J = 
10.5 Hz, 1H), 4.64 (dd,  J = 169.3, 11.4 Hz, 2H), 4.88-4.97 (m, 2H), 5.56 (dddd,  J = 17.2, 10.2, 
7.2, 7.2 Hz, 1H), 5.67 (dd,  J = 10.3, 1.1 Hz, 1H), 6.08 (dd, J = 17.6, 1.0 Hz, 1H), 6.22 (dd, J = 
17.6, 10.3 Hz, 1H), 7.24-7.41 (m, 11H), 7.61-7.67 (m, 4H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
19.3, 23.4, 27.2, 27.4, 29.3, 34.7, 36.1, 38.9, 41.3, 51.4, 57.9, 61.5, 68.0, 73.9, 81.0, 117.0, 127.6, 
127.7, 127.9, 128.4, 128.7, 129.6, 129.7, 134.4, 134.8, 136.1, 137.4, 137.8, 138.7, 178.6, 201.4. 
HRMS: C44H60O6NaSi, Calculated [M+Na]
+: 735.4057, Found [M+Na]+: 735.4046. [α]D20 = 
+17.5 (c = 1.0, CHCl3). 
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1.53 
(3R,4R,5R)-4-(benzyloxy)-5-((4S,6S)-6-((tert-butyldiphenylsilyl)oxy)hept-1-en-4-yl)-3-
methoxy-6,9-dioxopentadec-14-en-1-yl pivalate (1.53). Enone 1.77 (50.0 mg, 0.070 mmol) was 
suspended in 1,4-dioxane (1.4 mL) in a microwave vial. 3-Benzyl-5-(2-hydroxyethyl)-4-
methylthiazolium chloride (18.9 mg, 0.070 mmol) was added followed by triethylamine (14.7 mg, 
0.105 mmol) at room temperature. 6-hepten-1-al (1.78, 31.5 mg, 0.281 mmol) in 1,4 dioxane (0.2 
mL) was added and the vial was capped and heated to 70 °C for 12 h. The reaction was quenched 
by addition of water and extracted with dichloromethane. The extract was dried over sodium 
sulfate, condensed in vacuo, and purified by flash chromatography (0-15% ethyl acetate in 
hexanes) to give 1,4-dione 1.53 (37.0 mg, 64 %). 
1H NMR (CDCl3, 400 MHz)  (ppm): 0.99 (s, 12H), 1.18 (s, 9H), 1.33-1.42 (m, 2H), 1.52-1.68 
(m, 8H), 1.73-1.89 (m, 2H), 2.02-2.09 (m, 2H), 2.17-2.24 (m, 1H), 2.44 (t, J  = 7.3 Hz, 2H), 2.49-
2.57 (m, 2H), 2.59-2.70 (m, 1H), 2.89 (dd, J = 10.4, 3.0 Hz, 1H), 3.09 (d,  J = 8.9 Hz, 1H), 3.32 
(s, 3H), 3.92 (sext, J = 6.2 Hz, 1H), 4.05-4.09 (m, 1H), 4.18 (dd, J = 7.8, 5.5 Hz, 2H), 4.60 (dd,  J 
= 158.0, 11.4 Hz, 2H), 4.87-5.03 (m, 4H), 5.52 (dddd, J = 17.0, 10.1, 7.0, 6.9 Hz, 1H), 5.78 (dddd, 
J = 17.4, 10.4, 7.0 6.6 Hz, 1H), 7.23-7.40 (m, 11H), 7.62-7.67 (m, 4H). 13C NMR (CDCl3, 100 
MHz)  (ppm): 19.3, 23.3, 23.5, 27.2, 27.4, 28.6, 29.5, 33.7, 34.2, 35.6, 36.0, 38.9, 39.1, 41.3, 
42.8, 54.2, 57.8, 62.0, 68.1, 73.7, 81.0, 114.8, 116.9, 127.6, 127.6, 127.7, 127.9, 128.4, 129.6, 
129.7, 129.7, 134.6, 134.8, 136.1, 137.6, 138.7, 138.7, 178.6, 208.8, 210.3. HRMS: 
C51H72O7NaSi, Calculated [M+Na]
+: 847.4945, Found [M+Na]+: 847.4926. [α]D20 = +3.2 (c = 1.0, 
CHCl3). 
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1.79 
(3R,4R)-4-(benzyloxy)-4-((1R,2S)-2-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-10,13-
dioxocyclotridec-4-en-1-yl)-3-methoxybutyl pivalate (1.79). 1,4-dione 1.53 (85.0 mg, 0.103 
mmol) was suspended in anhydrous dichloromethane (206 mL) with a reflux condenser attached. 
Grubb’s first generation catalyst (25.4 mg, 0.031 mmol) was added and the resulting solution was 
stirred at 40 °C for 9 h. The reaction was cooled to room temperature and the dichloromethane was 
removed in vacuo. The dark brown residue was purified by flash chromatography (0-15% ethyl 
acetate in hexanes) to give a 1:1 mixture of the cis:trans macrocyclic alkene that were combined 
for the next reaction (69 mg, 84%). 
1H NMR (CDCl3, 400 MHz)  (ppm): 1.02 (s, 4.5 H), 1.03 (s, 4.5H), 1.04 (d, J = 6.2 Hz, 1.5 H), 
1.06 (d, J = 6.2 Hz, 1.5H), 1.18 (s, 4.5H), 1.19 (s, 4.5H), 1.42-1.53 (m, 4H), 1.62- 1.83 (m, 6H), 
1.84-1.93 (m, 2H), 1.97-2.04 (m, 2H), 2.10-2.14 (m, 1H), 2.15-2.23 (m, 1H), 2.27-2.32 (m, 0.5H), 
2.40-2.56 (m, 2H), 2.60-2.70 (m, 1H), 2.71-2.79 (m, 1H), 2.81-2.86 (m, 1H), 2.99 (ddd,  J = 15.4, 
10.0, 3.1 Hz, 0.5H), 3.13 (d, J = 10.0 Hz, 0.5H), 3.16-3.19 (m, 0.5H), 3.31 (s, 1.5H), 3.39 (s, 1.5H), 
3.78-3.83 (m, 1H), 3.89-3.92 (m, 1H), 4.10-4.13 (m, 1.5H), 4.16-4.22 (m, 1H), 4.57 (dd,  J = 276.2, 
11.3 Hz, 1H), 4.59 (dd,  J = 50.6, 11.9 Hz, 1H), 4.92-4.96 (m, 0.5H), 5.14-5.19 (m, 0.5H), 5.23-
5.31 (m, 1H), 7.26-7.42 (m, 11H), 7.61-7.69 (m, 4H).  13C NMR (CDCl3, 100 MHz)  (ppm): 
19.3, 19.3, 22.5, 22.6, 22.8, 22.9, 25.1, 26.9, 27.1, 27.2, 27.3, 27.4, 27.9, 29.7, 29.9, 30.0, 30.3, 
33.0, 34.6, 35.6, 35.8, 36.3, 38.7, 38.9, 40.3, 40.6, 41.2, 41.4, 51.8, 55.8, 58.0, 58.1, 61.5, 61.9, 
68.2, 68.4, 73.4, 78.1, 78.3, 79.8, 80.7, 126.4, 127.6, 127.7, 127.7, 127.7, 127.7, 128.0, 128.0, 
128.2, 128.4, 128.6, 128.7, 129.6, 129.7, 129.7, 131.9, 133.1, 134.6, 134.7, 136.0, 136.0, 136.0, 
138.0, 138.6, 178.6, 210.1, 210.1, 211.5, 211.8. HRMS: C49H68O7NaSi, Calculated [M+Na]
+: 
819.4632, Found [M+Na]+: 819.4630. 
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1.80 
(3R,4R)-4-(benzyloxy)-4-((2S,3S)-3-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-14-
azabicyclo[9.2.1]tetradeca-1(13),5,11-trien-2-yl)-3-methoxybutyl pivalate (1.80). Macrocyclic 
1,4-dione 1.79 (45.0 mg, 0.057 mmol) was suspended in anhydrous methanol (5.60 mL) in a 
microwave vial. Ammonium acetate (131 mg, 1.69 mmol) was added and the vial was capped and 
heated in the microwave at 120 °C for 20 min. The solution was cooled to room temperature, 
quenched with water, diluted with dichloromethane, and then extracted with dichloromethane. The 
extract was dried over sodium sulfate, condensed in vacuo, and purified by flash chromatography 
(0-15% ethyl acetate in hexanes) to give the  pyrrolophane 1.80 (40.0 mg, 91 %). 
1H NMR (CDCl3, 400 MHz)  (ppm): 0.88-0.90 (m, 1H), 0.97 (d, J = 6.6 Hz, 1H), 1.03 (s, 9H), 
1.04-1.07 (m, 4H), 1.09 (s, 9H), 1.20-1.33 (m, 4H), 1.50-1.65 (m, 5H), 1.71-1.89 (m, 2H), 2.47-
2.58 (m, 2H), 2.72 (bs, 1H), 3.16-3.24 (m, 1H), 3.27 (s, 3H), 3.78-3.87 (m, 1H), 3.90 (dd, J = 1.6, 
9.8 Hz, 1H), 4.05-4.12 (m, 2H), 4.61 (d, J = 11.5 Hz, 1H), 4.90 (d, J = 11.5 Hz, 1H), 5.08 (bs, 1H), 
5.18 (m, 1H), 5.63-5.80 (m, 2H), 7.27-7.41 (m, 11H), 7.65 (d, J = 6.5 Hz, 4H). 1H NMR (CDCl3, 
400 MHz)  (ppm): 0.82-0.91 (m, 1H), 1.00 (s, 9H), 1.04 (d, J = 6.0 Hz, 3H), 1.06-1.10 (m, 1H), 
1.13 (s, 9H), 1.17 (d, J = 9.3 Hz, 1H), 1.25 (s, 2H), 1.26-1.37 (m, 2H), 1.40-1.49 (m, 1H), 1.54 (s, 
9H), 1.55-1.61 (m, 1H), 1.62-1.72 (m, 2H), 1.75-1.92 (m, 4H), 2.05 (dd, J = 5.6, 9.4 Hz, 1H), 2.28-
2.37 (m, 1H), 2.42 (dt, J = 3.0, 13.6 Hz, 1H), 2.53 (m, 1H), 2.58 (dd, J = 4.7, 9.8 Hz, 1H), 3.19-
3.24 (m, 1H), 3.28 (s, 3H), 3.87 (sext, J = 6.9 Hz, 1H), 3.94 (dd, J = , 9.7 Hz, 1H), 4.07-4.18 (m, 
2H), 4.56 (d, J = 11.5 Hz, 1H), 4.69-4.79 (m, 1H), 4.93 (d, J = 11.5 Hz, 1H), 5.14-5.26 (m, 1H), 
5.53-5.66 (m, 2H), 7.27-7.42 (m, 11H), 7.65 (d, J = 7.3 Hz, 4H), 7.71 (bs, 1H). 13C NMR (CDCl3, 
150 MHz)  (ppm): 13.7, 14.1, 17.3, 17.3, 17.4, 19.1, 19.1, 20.4, 21.0, 21.2, 22.7, 27.0, 27.2, 27.7, 
29.3, 29.7, 30.6, 31.9, 56.0, 60.4, 64.4, 71.8, 96.1, 97.6, 99.8, 127.5, 128.8, 130.9, 132.4, 135.9, 
167.9, 170.9, 171.3. HRMS: C49H68NO5Si, Calculated [M+H]
+: 778.4867, Found [M+H]+: 
778.4865. [α]D20 = -5.4 (c = 0.3, CHCl3). 
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1.87 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-methoxy-5-
(((triisopropylsilyl)oxy)methyl)non-8-en-1-ol (1.87). Pivalate ester 1.54 (240 mg, 0.284 mmol) 
was suspended in anhydrous dichloromethane (28.0 mL) and cooled to -78 °C. 
Diisobutylaluminum hydride (1.0 M in dichloromethane, 0.850 mL, 0.852 mmol) was added 
dropwise, and the resulting solution was stirred for 1 h until TLC indicated the reaction was 
complete. The reaction was quenched by addition of saturated aqueous sodium potassium tartrate, 
warmed to room temperature, and stirred until the organic layer became clear. The mixture was 
extracted with dichloromethane, dried over sodium sulfate, and condensed in vacuo to give a clear 
oil. This oil was purified by flash chromatography (0-35% ethyl acetate in hexanes) to provide the 
desired free primary alcohol 1.87 as a clear, colorless oil (200 mg, 93%). 
1H NMR (CDCl3, 400 MHz) (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.1 Hz, 3H), 1.05 (s, 21H), 1.43 
(quin, J = 6.8 Hz, 1H), 1.57-1.63 (m, 1H), 1.65-1.74 (m, 2H), 1.75-1.81 (m, 1H), 1.98-2.07 (m, 
1H), 2.10-2.16 (m, 2H), 2.87 (d, J = 6.3 Hz, 1H), 3.41 (s, 3H), 3.58 (dd, J = 10.5, 6.2 Hz, 1H), 
3.66 (dd, J = 10.7, 3.6 Hz, 1H), 3.71-3.82 (m, 4H), 3.91 (sext, J = 6.1 Hz, 1H), 4.69 (dd, J = 156.8, 
11.4 Hz, 2H), 4.81-4.85 (m, 2H), 5.42-5.52 (m, 1H) 7.23-7.41 (m, 11H), 7.65-7.68 (m, 4H). 13C 
NMR (CDCl3, 100 MHz) (ppm): 12.1, 18.2, 19.3, 23.5, 27.1, 31.3, 33.0, 35.6, 42.9, 46.5, 57.0, 
61.4, 62.1, 68.6, 74.2, 78.2, 85.0, 115.6, 127.5, 127.5, 127.6, 128.0, 128.3, 129.5, 129.6, 134.6, 
135.1, 136.0, 138.6, 138.9. HRMS: C46H73O5Si2, Calculated [M+H]
+: 761.4997, Found [M+]+: 
761.4995. [α]D20 = -8.2 (c = 1.0, CHCl3). 
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1.88 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-methoxy-5-
(((triisopropylsilyl)oxy)methyl)non-8-enoic acid (1.88). Alcohol 1.87 (200 mg, 0.263 mmol) 
was suspended in dichloromethane/dimethylsulfoxide (4:1 v/v, 13.0 mL) and cooled to 0 °C. 
Triethylamine (0.370 mL, 2.63 mmol) was added followed by addition of sulfur trioxide pyridine 
complex (167 mg, 1.05 mmol). The resulting solution was stirred for 4 h at 0 °C, quenched by 
addition of water, extracted with dichloromethane, dried over sodium sulfate, and condensed in 
vacuo to give a pale yellow oil. This oil was purified by flash chromatography (0-20% ethyl acetate 
in hexanes) to provide the aldehyde as a clear, colorless oil (185 mg, 93%).  To a stirring solution 
of this aldehyde (182 mg, 0.240 mmol) in tert-butanol (9.00 mL) was added 2-methyl-2-butene 
(0.260 mL, 2.40 mmol). In a separate vial, monobasic sodium phosphate (252 mg, 1.82 mmol) was 
dissolved in water (9.00 mL) and sodium chlorite (163 mg, 1.80 mmol) was added. The tert-
butanol solution was cooled to 0 °C and the chlorite/phosphate solution in water was added 
dropwise. The resulting yellow solution was stirred at 0 °C for 30 min and was then quenched with 
saturated aqueous sodium thiosulfate and acidified to pH 3. The aqueous solution was then 
extracted with ethyl acetate, dried over sodium sulfate, and concentrated in vacuo to give a clear 
oil. This oil was purified by flash chromatography (0-50% ethyl acetate in hexanes) yielding 
carboxylic acid 1.88 as a clear, colorless oil (180 mg, 97%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.3 Hz, 3H), 1.04-1.06 (m, 21H), 
1.43 (quin, J = 6.7 Hz, 1H), 1.59-1.73 (m, 3H), 2.05-2.14 (m, 2H), 2.59 (dd, J = 16.5, 3.0 Hz, 1H), 
2.73 (dd, J = 16.3, 8.7 Hz, 1H), 3.60 (s, 3H), 3.57 (dd, J = 10.4, 6.4 Hz, 1H), 3.67 (dd, J = 10.9, 
3.9 Hz, 1H), 3.83 (dd, J = 9.0, 1.8 Hz, 1H), 3.90 (sext, J = 6.1 Hz, 1H), 4.05 (dt, J = 8.2, 2.2 Hz, 
1H), 4.68 (dd, J = 141.9, 11.4 Hz, 2H), 4.81-4.85 (m, 2H), 5.41-5.51 (m, 1H) 7.23-7.41 (m, 11H), 
7.64-7.67 (m, 4H). 13C NMR (CDCl3, 100 MHz) (ppm): 12.02, 18.22, 19.27, 23.42, 27.11, 
32.94, 35.08, 35.55, 42.86, 46.51, 57.47, 61.78, 68.56, 74.49, 77.35, 78.42, 80.90, 115.73, 127.50, 
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127.54, 127.63, 127.99, 128.34, 129.49, 129.61, 134.55, 135.08, 135.99, 136.01, 138.43, 138.67, 
176.17. 
 
 
1.89 
(3R,4R,5S,6S)-4-(benzyloxy)-6-((S)-2-((tert-butyldiphenylsilyl)oxy)propyl)-3-methoxy-5-
(((triisopropylsilyl)oxy)methyl)non-8-enamide (1.89). Acid 1.88 (225 mg, 0.290 mmol) was 
suspended in dimethylformamide (1.50 mL). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (83.4 mg, 0.440 mmol) and 1-hydroxybenzotriazole (58.8 mg, 0.440 mmol) were 
added subsequently at room temperature, followed by addition of diisopropylethylamine (0.200 
mL, 1.16 mmol) and ammonium chloride (31.0 mg, 0.580 mmol). The resulting solution was 
stirred for 6 h at room temperature until TLC indicated complete conversion. The reaction was 
quenched by addition of water, extracted with dichloromethane, dried over sodium sulfate, and 
condensed in vacuo to give a pale yellow residue. This residue was purified by flash 
chromatography (0-50% ethyl acetate in hexanes then 75% ethyl acetate in hexanes) to give amide 
1.89 as a clear colorless oil (180 mg, 80%). 
1H NMR (CDCl3, 400 MHz) (ppm): 1.00 (s, 9H), 1.02 (d, J = 6.1 Hz, 3H), 1.04-1.07 (m, 21H), 
1.44 (quin, J = 6.8 Hz, 1H), 1.63-1.73 (m, 3H), 2.01-2.08 (m, 1H), 2.16-2.22 (m, 1H), 2.43 (dd, J 
= 15.8, 3.0 Hz, 1H), 2.53 (dd, J = 15.8, 8.4 Hz, 1H), 3.41 (s, 3H), 3.62-3.71 (m, 2H), 3.86-3.95 
(m, 3H), 4.67 (dd, J = 124.8, 11.5 Hz, 2H), 4.79-4.84 (m, 2H), 5.16 (bs, 1H), 5.42-5.52 (m, 1H), 
5.98 (bs, 1H), 7.23-7.41 (m, 11H), 7.64-7.66 (d, J = 7.6 Hz, 4H). 13C NMR (CDCl3, 100 MHz) 
(ppm): 12.0, 18.9, 19.3, 23.5, 27.1, 33.1, 35.8, 36.4, 43.1, 46.1, 57.2, 61.7, 68.6, 74.3, 78.2, 81.0, 
115.6, 127.5, 127.5, 127.6, 127.8, 128.4, 129.5, 129.6, 134.7, 135.0, 136.0, 138.6, 138.9, 174.1. 
HRMS: C46H72NO5Si2, Calculated [M+H]
+: 774.4949, Found [M+H]+: 774.4951. [α]D20 = -15.4 
(c = 1.2, CHCl3). 
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1.90 
(3R,5S,6S,8S)-8-((tert-butyldiphenylsilyl)oxy)-3-methoxy-4-oxo-6-propyl-5-
(((triisopropylsilyl)oxy)methyl)nonanamide (1.90). Amide 1.89 (180 mg, 0.232 mmol) was 
suspended in anhydrous ethyl acetate (23.0 mL). 10% palladium on activated carbon (62.0 mg, 
0.058 mmol) was added and the flask was sealed and evacuated then back-filled with argon (3 x). 
The flask was then evacuated and refilled with hydrogen (3x) from a balloon. The reaction was 
stirred for 8 h at room temperature until the reaction was complete by TLC. The mixture was 
filtered through celite and washed liberally with ethyl acetate. The filtrate was condensed in vacuo 
to give the secondary alcohol as a clear, colorless oil that was carried on to the next step without 
further purification (158 mg, 99%). The resultant alcohol (152 mg, 0.222 mmol) was suspended 
in anhydrous dichloromethane (22.0 mL) with 4 Å molecular sieves (100 mg). The reaction was 
cooled to 0 °C and 4-methylmorpholine N-oxide (52.0 mg, 0.443 mmol) was added followed by 
tetrapropylammonium perruthenate (15.6 mg, 0.044 mmol). The reaction was warmed to room 
temperature and stirred for 2 h. Upon complete conversion as indicated by TLC, the mixture was 
filtered through celite and washed liberally with dichloromethane. The filtrate was condensed in 
vacuo to give a dark green residue that was purified by flash chromatography (0-75% ethyl acetate 
in hexanes) to give hydroxyketoamide 1.90 as a clear, colorless oil (129 mg, 85 %). 
1H NMR (CDCl3, 400 MHz) (ppm): 0.67 (t, J = 6.8 Hz, 3H), 0.79-0.93 (m, 3H), 1.02 (s, 30H), 
1.09 (d, J = 6.1 Hz, 3H), 1.25 (ddd, J = 13.7, 8.1, 4.1 Hz, 2H), 1.41 (ddd, J = 13.7, 8.9, 4.6 Hz, 
1H), 1.65-1.73 (m, 1H), 2.37 (dd, J = 14.8, 8.1 Hz, 1H), 2.59 (dd, J = 15.3, 4.1 Hz, 1H), 3.00 (ddd, 
J = 8.7, 6.8, 4.8 Hz, 1H), 3.38 (s, 3H), 3.70 (dd, J = 9.5, 4.7 Hz, 1H), 3.78-3.83 (m, 2H), 4.17 (dd, 
J = 8.1, 4.0 Hz, 1H), 5.27 (bs, 1H), 5.86 (bs, 1H), 7.34-7.43 (m, 6H), 7.65-7.68 (m, 4H). 13C NMR 
(CDCl3, 100 MHz) (ppm): 12.0, 14.5, 18.1, 18.8, 19.3, 22.8, 27.1, 32.3, 34.0, 37.0, 42.3, 53.1, 
58.3, 63.6, 68.2, 83.9, 127.7, 127.7, 129.7, 134.7, 136.0, 136.0, 172.0, 212.4. HRMS: 
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C39H66NO5Si2, Calculated [M+H]+: 684.4480, Found [M+H]+: 684.4485. [α]D20 = -17.4 (c = 0.5, 
CHCl3). 
 
 
1.91 
(4R,5R,7S,9S,10S)-4-methoxy-10-(methoxymethyl)-7-methyl-9-propyl-6-oxa-1-
azaspiro[4.5]decan-2-one (1.91). Hydroxyketoamide 1.90 (68.0 mg, 0.099 mmol) was suspended 
in anhydrous methanol (30.0 mL). Concentrated hydrochloric acid (0.026 mL, 0.300 mmol) was 
added at room temperature and the reaction was allowed to stir for 10 h. After this time the reaction 
was quenched by dropwise addition of saturated aqueous sodium bicarbonate and extracted with 
ethyl acetate. The organic layers were combined, dried over sodium sulfate, and condensed in 
vacuo to give a clear, colorless residue. The crude residue was purified by flash chromatography 
(0-85% ethyl acetate in hexanes) to yield the desired marineosin A model stereoisomer 1.91 as a 
clear, colorless oil (22.0 mg, 82%).  
1H NMR (CDCl3, 400 MHz) δ (ppm): 0.89-0.94 (m, 5H), 1.14-1.16 (m, 3H), 1.20 (d, J = 6.6 Hz, 
3H), 1.93-1.96 (m, 1H), 2.34-2.37 (m, 1H) 2.52 (m, 2H) 3.22 (dd, J = 10.4, 4.4 Hz, 1H), 3.28-3.31 
(m, 1H), 3.31 (s, 3H), 3.44 (s, 3H), 3.74-3.79 (m, 1H), 4.15 (dd, J = 9.6, 8.0 Hz, 1H), 6.23 (bs, 
1H). 13C NMR (CDCl3, 150 MHz) δ (ppm): 14.0, 22.2, 26.0, 30.6, 35.2, 40.6, 55.9, 58.2, 62.0, 
65.4, 70.4, 72.7, 79.2, 90.3, 175.3. 
 
 
1.92 
4-bromobutan-1-ol (1.92). To neat, refluxing tetrahydrofuran (67.5 mL, 832 mmol) was added 
48% aqueous hydrobromic acid (31.0 mL, 274 mmol) dropwise. The reaction mixture was held at 
reflux for 2 hours. After cooling to room temperature, the reaction was neutralized with saturated 
aqueous sodium bicarbonate, extracted with diethyl ether, dried over sodium sulfate, and 
concentrated to provide 31.4 g (75%) of alcohol 1.92.  Spectral data matches that of commercial-
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grade material. 
 
 
1.94 
2-(4-bromobutoxy)tetrahydro-2H-pyran (1.94). To a stirred solution of alcohol 1.92 (1.95 g, 
12.7 mmol) in diethyl ether (12.0 mL) at 0 °C was added p-TsOH (5.00 mg, 0.02 mmol) followed 
by dropwise addition of 3,4-dihydro-2H-pyran 1.93 (1.50 mL, 16.6 mmol). The reaction mixture 
was allowed to warm to room temperature. After 1 h, the reaction mixture was washed with 
saturated aqueous sodium bicarbonate and brine. The organic layer was dried over potassium 
carbonate, filtered, and concentrated to provide 2.70 g (90%) of pyran 1.94. Spectral data matches 
that recorded by Grieco, et al.32  
 
 
1.97 
(R)-3-hydroxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.97). To a solution of (R)-2- 
hydroxysuccinic acid 1.96 (3.20 g, 24.0 mmol) in 50% aqueous methanol (5 mL) was slowly added 
para-methoxybenzyl amine (3.14 mL, 24.0 mmol). Methanol was removed under reduced pressure 
and the reaction mixture was partitioned with m-xylene (64 mL) and heated to 190 °C. Water was 
azeotropically removed with a Dean-Stark trap. After 24 hours, the solvent was removed under 
reduced pressure and the residue was partitioned with ethanol (25 mL) and concentrated. 
Recrystallization from benzene provided 4.40 g (78%) of maleimide 1.97. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.66 (dd, J = 4.8, 18.2 Hz, 1H), 2.93 (bs, 1H), 3.05 (dd, J = 
8.5, 18.2 Hz, 1H), 3.78 (s, 3H), 4.56-4.65 (m, 3H), 6.83 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 
2H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 37.1, 41.8, 55.2, 66.8, 113.9, 127.4, 130.3, 159.3, 
174.0, 178.3. HRMS: C12H13NO4Na, Calculated [M+Na]
+: 258.0742, Found [M+Na]+: 258.0741.  
[α]D20 = +43.1 (c = 1.0, CH3OH). 
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1.98 
(R)-3-methoxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (1.98). To a solution of maleimide 
1.97 (4.15 g, 20.3 mmol) in acetonitrile (40 mL) at room temperature was added silver(I) oxide 
(4.69 g, 20.3 mmol) and iodomethane (3.60 mL, 57.9 mmol). The reaction mixture was refluxed 
for 1 h. After cooling to room temperature, the reaction mixture was filtered, concentrated, and 
purified by column chromatography (0-20% ethyl acetate in hexanes) to provide 3.92 g (78%) of 
ether 1.98. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.60 (dd, J = 4.2, 18.2 Hz, 1H), 2.98 (dd, J = 8.2, 18.2 Hz, 
1H), 3.60 (s, 3H), 3.78 (s, 3H), 4.18 (dd, J = 4.2, 8.2 Hz, 1H), 4.59 (d, J = 2.4 Hz, 2H), 6.83 (d, J 
= 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 35.5, 41.3, 54.9, 
58.4, 74.5, 113.7, 127.5, 123.0, 159.0, 173.6, 175.1. HRMS: C13H15NO4Na, Calculated [M+Na]
+: 
272.0899, Found [M+Na]+: 272.0900. [α]D20 = +45.7 (c = 1.0, CH3OH). 
 
 
1.99 
(4R)-5-hydroxy-4-methoxy-1-(4-methoxybenzyl)-5-(4-((tetrahydro-2H-pyran-2- 
yl)oxy)butyl)pyrrolidin-2-one (1.99). A flame-dried flask was charged with magnesium powder 
(447 mg, 18.4 mmol) and placed under an inert argon atmosphere. The magnesium was suspended 
in anhydrous tetrahydrofuran (21.0 mL) and pyran 1.94 (1.40 mL, 7.50 mmol) was added. After 
warming to 50 °C, additional pyran 1.94 (2.00 mL, 10.7 mmol) was added dropwise. The reaction 
mixture was heated periodically until it sustained reflux. A separate flame-dried flask was charged 
with ether 1.98 (1.50 g, 6.00 mmol) and THF (30.0 mL). After cooling to −20 °C, the solution of 
Grignard 1.95 was added dropwise via syringe. The reaction mixture was kept between −10 °C 
and −15 °C. After 2.5 h, water (5.00 mL) was added and the reaction was allowed to reach room 
temperature. The product was extracted with diethyl ether, washed with brine, dried over sodium 
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sulfate, and concentrated. The residue was purified on by column chromatography (0-30% ethyl 
acetate in hexanes) to provide 6.61 g (80%) of tertiary alcohol 1.99. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.48-1.59 (m, 5H), 1.61-1.75 (m, 2H), 1.77-1.90 (m, 1H), 
2.12-2.24 (m, 2H), 2.57 (d, J = 17.9 Hz, 1H), 2.71 (dddd, J = 1.9, 7.2, 17.8 Hz, 1H), 3.27 (s, 3H), 
3.29-3.34 (m, 1H), 3.45-3.50 (m, 1H), 3.63-3.71 (m, 1H), 3.77 (s, 3H), 3.80-3.85 (m, 1H), 4.49-
4.52 (m, 1H), 4.55- 4.66 (m, 3H), 4.85 (q, J = 6.8 Hz, 1H), 6.81 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 
8.6 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 19.6, 19.8, 23.4, 23.5, 25.4 (2C), 30.1, 30.2, 
30.7, 30.8, 36.0 (2C), 42.9 (2C), 55.1, 55.2, 62.3, 62.6, 66.5, 66.7, 72.0 (2C), 98.9, 99.0, 107.0, 
107.1, 113.9 (2C), 127.9, 128.3, 128.4, 139.2, 139.3, 158.8 (2C), 173.0, 173.1. HRMS: 
C22H33NO6Na, Calculated [M+Na]
+: 430.2206, Found [M+Na]+: 430.2210. [α]D20 = -15.0 (c = 0.6, 
CHCl3).  
 
 
1.101 
(4R,5S)-4-methoxy-1-(4-methoxybenzyl)-6-oxa-1-azaspiro[4.5]decan-2-one (1.101). To a 
stirred solution of tertiary alcohol 1.99 (390 mg, 1.00 mmol) in dichloromethane (6.00 mL) at 0 
°C was added p-TsOH monohydrate (41.0 mg, 0.200 mmol). After 30 minutes, the solvent was 
removed and the residue was purified by flash chromatography (0-30% ethyl acetate in hexanes) 
to provide 244 mg (80%) of spiroaminal 1.101. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.39-1.51 (m, 4H), 1.63-1.70 (m, 1H), 1.85-1.92 (m, 1H), 
2.47 (d, J = 17.4 Hz, 1H), 2.65 (dd, J = 5.5, 17.4 Hz, 1H), 3.32 (s, 3H), 3.61 (m, 1H), 3.73 (s, 3H), 
3.84 (dd, J = 2.4, 11.2 Hz, 1H), 3.95 (d, J = 5.5 Hz, 1H), 4.11 (d, J = 16.0 Hz, 1H), 4.70 (d, J = 
16.0 Hz, 1H), 6.78 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ 
(ppm): 20.0, 24.6, 27.9, 34.3, 41.8, 55.0, 56.6, 64.7, 74.9, 94.9, 113.5, 127.9, 130.5, 158.2, 174.5. 
HRMS: C17H24NO4, Calculated [M+H]
+: 306.1705, Found [M+H]+: 306.1702. [α]D20 = -50.6 (c = 
1.0, CHCl3). 
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1.102 
(4R,5S)-4-methoxy-6-oxa-1-azaspiro[4.5]decan-2-one (1.102). To a stirred solution of 
spiroaminal 1.101 (258 mg, 0.850 mmol) in acetonitrile (27.0 mL) and water (3.50 mL) was added 
ceric ammonium nitrate (1.40 g, 2.50 mmol). After 1.5 h, a second portion of CAN (467 mg, 0.800 
mmol) was added. After 1 h, the acetonitrile was removed under reduced pressure and the product 
was extracted with dichloromethane. The combined organic layers were washed with brine, dried 
over sodium sulfate, and concentrated. The residue was purified by column chromatography (0-
30% ethyl acetate in hexanes) to provide 105 mg (67%) of amide 1.102. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.54-1.63 (m, 2H), 1.63-1.73 (m, 1H), 1.73-1.83 (m, 3H), 
2.29 (dd, J = 1.7, 17.2 Hz, 1H), 2.70 (dd, J = 5.6, 17.2 Hz, 1H), 3.34 (s, 3H), 3.66-3.72 (m, 3H), 
8.64 (bs, 1H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 19.4, 25.2, 29.3, 35.7, 57.3, 62.7, 82.4, 91.8, 
177.3. HRMS: C9H16NO3, Calculated [M+H]
+: 186.1130, Found [M+H]+: 186.1131. [α]D20 = -
97.1 (c = 1.1, CHCl3). 
 
 
1.105 
(4R,5S)-4-methoxy-2-(1H-pyrrol-2-yl)-6-oxa-1-azaspiro[4.5]dec-1-ene (1.105). A flame dried 
flask was charged with amide 1.102 (30.0 mg, 0.162 mmol) and placed under an inert argon 
atmosphere. After cooling to 0 °C, anhydrous dichloromethane (1.60 mL) and 
trifluoromethanesulfonic anhydride (27.0 μL, 0.162 mmol) were added. After 3 minutes, pyrrole 
(56.0 μL, 0.810 mmol) was added and at 10 minutes, the reaction was quenched with saturated 
aqueous sodium bicarbonate. The product was extracted with DCM, dried over sodium sulfate, 
and concentrated. The residue was purified by flash chromatography (0-70% ethyl acetate in 
hexanes) to provide 30.5 mg (80%) of pyrrole 1.105. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.54-1.78 (m, 5H), 1.86-1.99 (m, 2H), 2.78 (dd, J = 5.3, 
16.5 Hz, 1H), 3.21 (dd, J = 6.8, 16.5 Hz, 1H), 3.44 (s, 3H), 3.72 (d, J = 10.8 Hz, 1H), 3.84 (t, J = 
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6.2 Hz, 1H), 4.15 (dt, J = 2.8, 11.1 Hz, 1H), 6.21 (t, J = 3.2 Hz, 1H), 6.57 (d, J = 3.5 Hz, 1H), 6.90 
(s, 1H). 13C NMR (CDCl3, 100 MHz) δ (ppm): 19.6, 25.8, 29.2, 38.7, 58.2, 64.2, 85.3, 102.8, 
110.7, 112.8, 121.1, 126.3, 164.6. HRMS: C13H19N2O2, Calculated [M+H]
+: 235.1447, Found 
[M+H]+: 235.1447. [α]D20 = -65.2 (c = 1.6, CHCl3). 
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Chapter II 
 
Synthesis and Optimization of a Selective Dopamine Receptor 4 Antagonist for Use as a 
PET Tracer and an in vivo Tool to Study Cocaine Addiction 
 
2.1. Introduction 
 Dopamine receptors are involved in many important central nervous system (CNS) 
processes and are indicated in diseases such as schizophrenia, attention deficit hyperactivity 
disorder (ADHD), Parkinson’s disease (PD), and substance addiction.33  Since the discovery of 
five subtypes of the dopamine receptors, great effort has been made to synthesize highly selective 
ligands in order to study each receptor’s involvement in disease.  To this end, this chapter reports 
on the structure-activity relationship (SAR) of a novel, morpholine-based dopamine receptor 4 
(D4) antagonist.  The goal of this project is to optimize this scaffold to be an in vivo probe as well 
as a positron emission tomography (PET) tracer to study the role of D4 receptors in cocaine 
addiction.   
 
2.1.1. Dopamine Receptors 
 Dopamine (DA, Figure 2.1) is an important catecholamine neurotransmitter in mammals 
and is the endogenous ligand of five distinct dopamine receptors.33  The dopamine receptors are 
G-protein coupled receptors (GPCRs) that fall into two families based on their homology and 
function: the D1-like family (D1 and D5) and the D2-like family (D2, D3, and D4) (Figure 2.1).  D1 
and D2 receptors are the most numerous DA receptors in the CNS and the earliest to be discovered.  
Conversely, it took almost twenty years to discover the D3, D4, and D5 receptors, which have 
relatively low levels of expression.34  The D1-like family couples to Gαs/olf proteins, leading to 
activation of the enzyme adenylyl cyclase (AC) and an increase in cyclic adenosine 
monophosphate (cAMP) levels.  The D2-like family couples to Gαi/o proteins which induce the 
opposite effect from Gαs/olf proteins, inhibition of AC and a decrease of cAMP concentrations.33  
As a member of the D2-like family, D4 is 53% homologous to the D2 receptor in its transmembrane 
domain, making the development of a selective ligand difficult.33 
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Figure 2.1.  (a) Structure of dopamine. (b) The dopamine receptor families. 
 
 Dopamine regulation through the nigrostriatal, mesolimbic, and mesocortical pathways has 
been shown to be involved in reward, motivation, motor control, and cognition.35  It has been 
shown that high levels of DA can lead to increased motor activity and “impulsive” behaviors while 
low levels can cause torpor and slowed reaction.33  There are many CNS conditions associated 
with dopaminergic dysfunction, including Parkinson’s disease, attention deficit hyperactivity 
disorder, Tourette’s syndrome, and psychoses as seen in schizophrenia, Huntington’s disease, and 
Alzheimer’s disease.34   
The D1 and D2 receptors have been explored in greater depth than the other DA receptors 
and have been shown to be critically involved in reward, reinforcement, and locomotor activity.36  
Most information reported about the D4 receptor’s function is highly debated.  Knockout studies 
of the D4 receptor gene (DRD4) show phenotypes suggesting a physiological role for D4 in 
locomotion and drug sensitivity.34  DRD4 knockout mice demonstrated a reduction in overall 
locomotion and were more sensitive to the stimulation of locomotor activity elicited by cocaine.35  
Genetic association studies have also added relevant information about the role of D4 in various 
disease states, showing a strong association for D4 with ADHD, alcoholism, and nicotine 
dependence (Figure 2.2).37  However, these results are preliminary data that must be studied in 
animal models using selective D4 ligands to confirm the association. 
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Figure 2.2.  D4 involvement in disease as shown by genetic association studies.
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There are a number of polymorphisms in the D4 receptor gene coding sequence.  The most 
extensive is found in the third exon that encodes the third intracellular loop (IL3) of the receptor.  
This exon contains a variable number of tandem repeats (VNTR), in which a 48-base pair sequence 
(16 amino acids) exists as a 2- to 11-fold repeat (D4.2 to D4.11).
38  A similar polymorphism has been 
found in primates and dogs, but not in rodents.38  In the global population of humans, D4.4 is the 
most common at 64%, D4.7 is found in 21% of people, and D4.2 is 8% abundant.
34  Correspondingly, 
there are two isoforms of the D2 receptor, D2L and D2S.  The D2L receptor (dopamine receptor 2 
long form) contains a 29 amino acid insertion in the IL3 that is not observed in the D2S receptor 
(dopamine receptor 2 short form).35  The variations found in the third intracellular loop of the 
dopamine receptors could be important regarding their coupling to G-proteins.  However, any 
differences in function have not been defined and ligand binding affinity for D4 does not 
significantly change across polymorphisms. 
D4 receptors have been found to be expressed in the cerebral cortex, amygdala, 
hippocampus, and striatum through studies such as Northern blot, reverse transcription polymerase 
chain reaction, and in situ hybridization.38  It is also been demonstrated that D4 is highly expressed 
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in the retina.  D4 receptors are not exclusive to the brain; they are also present in the cardiac atrium, 
lymphocytes, and kidneys.38  D4 receptors are postsynaptic and their stimulation not only inhibits 
adenylyl cyclase, but also inositol phosphate hydrolysis and arachidonic acid release.  Stimulation 
also causes the opening of G-protein coupled inward rectifying potassium channels (GIRK) and 
the closing of calcium channels (Figure 2.3).34   
 
 
Figure 2.3.  The D4.2 receptor and its signaling cascade.
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2.1.2. PET Imaging 
 Positron emission tomography is a technique that has become commonplace in the drug 
discovery and medical communities.  PET is a non-invasive procedure that uses positron emitting 
isotopes to measure the uptake, location, concentration, and elimination of a labeled molecule in 
the body.39  The radioisotope undergoes beta decay, emitting positrons from its nucleus which 
travel through the local tissue until they interact with an electron, annihilating both.40  This 
collision produces a pair of gamma photons that travel at the same speed but roughly 180 degrees 
from each other.  When the photons reach the detectors surrounding the test subject, light is 
produced and converted to an electrical signal, allowing a computer to design an image revealing 
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where the photons originated.40  The total analysis reveals the locations with the highest 
concentrations of the labeled PET tracer.  
 There are many isotopes that can be used in PET imaging including nitrogen-13, oxygen-
15, bromine-76, and iodine-124.41  However, the most commonly used isotopes are carbon-11 (for 
its convenient incorporation into organic molecules) and fluorine-18 (for its reasonable half-life of 
110 minutes).41   
 
2.2. Literature Review 
 
2.2.1. Dopamine Receptor 4 Antagonists 
 There has long been interest in small molecule regulation of dopamine receptors.  
Dopamine receptor 4 antagonists quickly gained attention in the mid-1990s after it was found that 
clozapine (Figure 2.4) binds to D4 with a higher affinity than D2 (Table 2.1).  Clozapine is an 
atypical antipsychotic used to treat schizophrenia and while it does bind D4 receptors, it also 
inhibits the serotonin (5-HT), muscarinic (M), adrenaline (α), and histamine (H) receptors.42,43  
Scientists once thought that clozapine’s efficacy in schizophrenia was due to its activity at D4, 
beginning the race to synthesize selective D4 antagonists.  This hypothesis was later found to be 
incorrect.  Shown in Table 2.1 is a summary of antagonists that are at least 500-fold selective for 
D4 over D2.  The structures of these antagonists all contain 1,4-disubstituted piperidine or 
piperazine cores (Figure 2.4, highlighted in red).  While their selectivity for D4 over D2 is good, 
the basicity of the alkylated nitrogen causes many of these compounds to have activity at other 
biogenic amine receptors, limiting their use as tool compounds. 
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Figure 2.4.  Structures of “selective” D4 antagonists. 
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Table 2.1.  Summary of D4 antagonists with >500-fold selectivity over D2. 
 
 
 Of particular interest to the work presented in this chapter, there has been a report of 2,4-
disubstituted morpholines as D4 ligands.  Table 2.2 summarizes an SAR study of D4 antagonists 
containing morpholine and oxazepane cores.44  Shown are compounds that exhibited greater than 
10 nM binding affinity for D4.2.  All compounds were also tested against D2, with none having 
activity up to 10 µM; however, activity at other receptors was not reported.  Using their modeling 
software, the group concluded that the two π system substituents and the basic nitrogen of the core 
are necessary to maintain high affinity and selectivity for D4 receptors.
44 
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Table 2.2.  SAR of morpholines and oxazepanes as D4 ligands.
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2.2.2. Cocaine Addiction 
 There have been many studies showing that long alleles of DRD4 (greater than 7 repeats 
in the third intracellular loop) are implicated in personality traits such as excessive impulsivity, 
novelty-seeking, and risk-taking behavior.45  These traits play a large factor in drug-taking 
behavior, leading to studies of the D4 receptor’s involvement in addiction.  While many genetic 
association studies have been debated, there is evidence of a higher prevalence of DRD4 long 
alleles in methamphetamine and nicotine users.45  These results need to be confirmed by the 
development and use of animal models with selective ligands of the D4 receptor.   
Initial studies using DRD4 knockout mice were inconclusive with respect to the gene’s role 
in drug-taking behavior, so alternative animal models are more useful to study addiction.45  There 
are several models that can be used to test stimulant-taking behavior, with drug self-administration 
as the gold standard to study drugs of abuse.  The Lindsley lab is especially interested in the ability 
of D4 antagonists to treat cocaine addiction and its symptoms.  Cocaine addiction is a widespread 
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problem, with approximately 4.8 million Americans having abused the drug in 2009, and there are 
currently no approved medications for its treatment.46   
In the clinic, both D1 and D2 antagonists failed to reduce the symptoms patients claimed to 
experience due to cocaine addiction.  Buspirone (Figure 2.5), an FDA-approved drug for 
generalized anxiety disorder, acts as an antagonist at the D3 and D4 receptors (Kis of 98 and 29 
nM, respectively) but is commonly characterized as a serotonin 5-HT1A partial agonist (Ki = 29 
nM).43,46  Bergman and co-workers studied buspirone in intravenous cocaine self-administration 
models in nonhuman primates (NHP), and found that cocaine intake was completely extinguished 
with buspirone pretreatment in the range of currently prescribed oral doses (Figure 2.5).46  These 
results were not seen in food-maintained behavior, suggesting no effect on motivation due to 
buspirone treatment.  The authors propose that these results are not due to buspirone’s 5-HT1A 
activity, as a previously tested 5-HT1A selective agonist, gepirone (Figure 2.5), did not produce 
changes in self-administration behavior.46  There have been other studies using D4 antagonists in 
various cocaine addiction models with results that are intriguing but incomplete.47   
 
 
Figure 2.5.  Efficacy of buspirone to attenuate cocaine self-administration in NHP. 
 
While our lab is mainly interested in cocaine addiction, other stimulants like nicotine and 
amphetamines have been studied in relation to D4.  Yan et al. showed that L-745,870 (Figure 2.4) 
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blocked the reinstatement of nicotine-seeking brought on by either reexposure to nicotine or cues 
paired with the drug.48  They also found that L-745,870 did not affect reinstatement of food-
seeking.  This suggests that D4 receptors are involved in drug-seeking relapse and D4 antagonists 
could prolong abstinence; however, other stimulants should be tested to confirm this hypothesis.  
Another study demonstrated that D4 receptors play a role in behavioral sensitization to 
amphetamine in rats.49  When PNU-101,387 (Figure 2.4) was dosed with amphetamine, the 
amphetamine-induced increase in dopamine release was blocked.49  This finding reveals the 
possibility that D4 is important in the establishment of addiction through the development of 
sensitization to drugs of abuse.   
 The D4 receptor has been shown not to be involved in the rewarding effects of stimulants 
through drug discrimination and conditioned place preference models.45  Instead, it seems D4 may 
mediate relapse and other aspects of stimulant-seeking as seen in self-administration, 
reinstatement, and sensitization models.45  This is a fascinating therapeutic area for D4 antagonists 
as research continues to uncover information about the possible treatment of cocaine addiction. 
 
 2.2.3. PET Imaging of Dopamine 4 Receptors 
 Various techniques like autoradiography and receptor-specific antibodies have been used 
to determine the location of D4 receptors in the brain.
50  These studies have led to general 
conclusions about where D4 is expressed and have found that D4 receptor densities are quite low 
in the brain.  To detect small receptor populations using PET, a radioligand must have very high 
binding affinity (generally picomolar range), complete selectivity for its target, high blood-brain 
barrier (BBB) penetrance, and low nonspecific binding.51  Important to these last two criteria is 
the tracer’s lipophilicity, with optimum log P values for CNS drugs being 2.0 to 3.5.51   
There are several reports in which compounds with high affinity for D4 and reasonable 
selectivity have been analyzed as potential PET tracers.  Many of these failed to attain PET tracer 
status due to factors like rapid metabolism and nonspecific binding.  Only a few studies have 
attempted to use PET to image D4 receptors.  PB-12 (Table 2.3) is one such compound; it is highly 
selective over the other dopamine receptors (>17,000-fold) and, although it shows activity at 
serotonin and adrenergic receptors, PB-12 is still maintains >3,800-fold selectivity.52 
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Table 2.3.  Reported potencies of PB-12.52 
 
 
 PB-12 was labeled with carbon-11 at the methoxy carbon and used in PET imaging in a 
cynomolgus monkey.50  After injection of [11C]PB-12, rapid and high accumulation of 
radioactivity in the brain was seen, revealing no specific binding.  Two separate experiments were 
performed using a pretreatment of L-745,870 or unlabeled PB-12 thirty minutes before injection 
of the radioligand.  It would be expected that the D4 receptors would be blocked by these 
antagonists resulting in an observable difference in the PET images.  However, this effect was not 
seen, as no change in radioligand distribution was observed, again suggesting that the radioactivity 
detected was due to nonspecific binding.50  Langer et al. postulated that this result may be caused 
by the lipophilicity of PB-12 (log P = 3.25) being high enough to bind to many other proteins and 
lipids in the brain.50 
 The scaffold of PB-12 continued to be used as a lead to find D4 antagonists with lower 
lipophilicity.  A report from 2010 revealed that the binding affinity of PB-12 is actually much 
lower than previously reported (Ki = 5.0 nM).
51  This may have led to the failure of the initial study 
summarized above.  This new study identified 2.1 (Table 2.4) as a potentially improved PET 
tracer.  Piperidine 2.1 showed no significant displacement of specific ligands for the receptors 
shown below at 1 µM and was also less lipophilic than PB-12 (log P = 2.55). 
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Table 2.4.  Structure and binding data of 2.1.51 
 
 Intravenous injection of [11C]2.1 into a rhesus monkey showed swift uptake in all brain 
regions followed by a rapid decline of radioactivity.51  This suggests no specific or nonspecific 
binding occurred; however, radioactive accumulation in the retina was seen.  Lacivita et al. 
concluded that imaging D4 receptors using PET would require a ligand with a higher binding 
affinity than 1.5 nM due to low receptor density.51 
 The promise of a D4 antagonist as a treatment for cocaine addiction as well as the lack of 
successful PET tracers for D4 are the basis for our interest in developing a highly selective and 
potent D4 antagonist. 
 
2.3. Preliminary Data 
 The lead compound for this project was first reported in a Merck patent in 1995 followed 
by a subsequent publication.53,54  Morpholine 2.5 was claimed to be a selective D4 antagonist with 
one enantiomer being preferred, but the active stereoisomer was not reported.  Morpholine 2.5 was 
prepared in three steps, including a chiral high-performance liquid chromatography (HPLC) 
purification to obtain the individual enantiomers in 10% overall yield (Scheme 2.1a). 
 The Lindsley lab chose to synthesize this pharmaceutically relevant morpholine based on 
our recently developed methodology (Scheme 2.1b).55  Inspired by Jørgensen’s work, 4-
phenylbutanal (2.6) was asymmetrically α-chlorinated with pyrrolidine catalyst 2.7 and the 
resulting aldehyde was immediately reduced with sodium borohydride (NaBH4) to preserve 
enantiopurity.56  Alcohol 2.8 was converted into a leaving group with triflic anhydride (Tf2O) and 
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displaced with N-benzylethanolamine.  The primary alcohol was then free to perform SN2 
displacement of the chlorine, inverting the stereochemistry at that carbon.  Hydrogenation of the 
benzyl protecting group and N-alkylation with benzimidazole 2.4 delivered (R)-2.5.  This route 
greatly improved upon the previously reported synthesis with up to 95% enantiomeric excess (ee) 
and 35% overall yield.  
  
Scheme 2.1.  Synthesis of morpholine 2.5 from (a) Merck, 199553 and (b) Lindsley, 201255. 
 
 Both enantiomers and the racemate of morpholine 2.5 were synthesized and evaluated 
against the full family of dopamine receptors in binding assays (Table 2.5).  Morpholine 2.5 is 
completely inactive at D1, D2, and D5, and >75-fold more selective for D4 than D3.  Additionally, 
only the (R)-enantiomer is active at the D4 receptor with Ki = 70 nM and IC50 = 180 nM. 
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Table 2.5.  Binding and potency of the enantiomers of 2.5 against the dopamine receptors.55 
 
 
 VU0469118 ((R)-2.5) was subsequently submitted for drug metabolism and 
pharmacokinetics (DMPK) studies to determine its potential as an in vivo probe and PET tracer.  
Table 2.6 describes the DMPK characteristics desired for such a ligand and compares them to the 
properties of VU0469118.  VU0469118 meets almost all of the desired qualities for an in vivo tool.  
It has a high free fraction, ideal ClogP, high brain exposure, and no significant activity against any 
of the 68 GPCRs, ion channels, and transporters in the Lead Profiling Screen at Eurofins.  The 
properties that still need to be improved upon for VU0469118 to become an in vivo tool are the 
binding affinity and the clearance, which is where our SAR study will focus.  The SAR study for 
VU0469118 as a PET tracer will focus on incorporating a handle for radiolabeling and improving 
binding affinity. 
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Table 2.6.  Desired and actual characteristics of VU0469118. 
 
2.4. Structure-Activity Relationship Study of VU0469118 
 There are three obvious functionalities of VU0469118 to study SAR – the western phenyl, 
the benzimidazole, and the morpholine core (Figure 2.6).  The benzimidazole substituent was 
chosen to study first as its addition was the final step of the known synthetic route to access 
VU0469118.  A new route was devised to synthesize western phenyl derivatives so that the 
diversification step was closer to the end of the synthesis.  Also, many core modifications were 
planned to study SAR. 
 
 
Figure 2.6.  Functionalities of VU0469118 to derivatize: western phenyl (green), morpholine 
core (blue), benzimidazole (pink). 
 
2.4.1. Benzimidazole Derivatives 
 In order to synthesize derivatives of the benzimidazole, the previously described synthesis 
of VU0469118 was employed using DL-proline as the catalyst for α-chlorination (Scheme 2.2).57  
It was important to synthesize this library as the racemate because changing the substituent on the 
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morpholine nitrogen could switch the enantiopreference of the receptor for the ligand.  After 
common intermediate 2.3 was synthesized, the derivitization steps were optimized for rapid library 
synthesis and purification of the crude material via automated reverse-phase HPLC with minimal 
workup.  Five different types of linkages off the morpholine nitrogen were studied in this initial 
library.  All compounds were submitted to Eurofins Panlabs where they were tested at a single 
point of 10 µM in a competition study of D4 receptors incubated with [
3H]spiperone (Kd = 0.46 
nM).  The results were considered significant if the percent inhibition was greater than 50%, 
meaning that 50% of the radioligand was displaced from the receptor by our compound.   
 
Scheme 2.2.  Route to the library of benzimidazole derivatives. 
 
 The synthesis and inhibition data of benzyl linked derivatives is shown in Figure 2.7.  
Structure-activity relationship information was immediately evident from the data collected for 
these compounds.  Para-substituted benzyl derivatives were preferred while substitutions at the 
ortho and meta positions were less active.  Also, all isomers of the pyridyl substituent were 
inactive.57 
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Figure 2.7.  Synthesis and inhibition data of benzyl linked derivatives. 
 
 Other types of linkages were studied off the morpholine nitrogen as well.  Scheme 2.3 
shows the synthesis of amides, ureas, sulfonamides, and N-aryl derivatives.  As shown in Table 
2.7, none of these compounds were considered active.  Interestingly, when compared to the 
identical aryl groups that were benzyl linked, a significant loss in inhibition is seen.57 
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Scheme 2.3.  Synthesis of amides, ureas, sulfonamides, and N-aryl derivatives. 
 
Table 2.7.  Inhibition comparison of benzyl linked derivatives to other linkages.   
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 Figure 2.8 provides a summary of the inactive compounds from this first library.  Any 
compound lacking a methylene between the nitrogen and aryl group proved to be inactive.  Pyridyl 
derivatives also did not significantly inhibit spiperone’s binding to the D4 receptor.  There are a 
few theories as to why this SAR appears: (1) the basicity of the nitrogen, which is key for binding, 
could be greatly reduced; (2) a specific length of linker may be necessary to fill a pocket of the 
binding site; (3) an oxygen coming off the linker could have unfavorable steric and/or electronic 
interactions in the pocket. 
 
 
Figure 2.8.  Summary of inactive compounds with <35% inhibition of D4. 
 
 Additional binding data was obtained for the active compounds (Table 2.8).  VU0517161 
exhibited a 98% inhibition corresponding to 46 nM Ki and 170 nM IC50.  VU0517057 was slightly 
less active with a 97% inhibition, 81 nM Ki, and 290 nM IC50.  Importantly, this library was 
racemic, and it was expected that one stereoisomer would be more active than the other. 
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Table 2.8.  Summary of active compounds and their binding affinity. 
 
 
Next, the (R)- and (S)-enantiomers of the top two compounds were resolved and tested.  
The (R)-enantiomer was once again confirmed as the active isomer.   Selectivity data was also 
attained for the dopamine receptors (Table 2.9).  VU0603864, with the para-methoxy substituent, 
had the highest binding affinity of 28 nM.  However, it did have slight activity at D2L and D3, but 
maintained 100-fold selectivity over these receptors.  VU0603865 (R = Cl) exhibited a binding 
affinity of 36 nM and greater than 20 µM potency across the other dopamine receptors, showing 
excellent selectivity.57   
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Table 2.9.  Dopamine receptor binding data. 
 
 
 VU0603865 was chosen for further DMPK testing due to its complete selectivity and high 
affinity for the D4 receptor (Table 2.10).  Similar to VU0469118, VU0603865 was predicted to 
have high clearance in both rat and human.  VU0603865 had good free fraction in both species 
and showed no significant activity against cytochrome P450 (CYP) enzymes, an improvement 
over the initial hit.  In an in vivo tissue distribution study, VU0603865 was found to readily cross 
the blood-brain barrier with total brain concentrations of ~1 µM at 15 minutes.  This compound 
was also tested in Eurofins Lead Profiling screen of 68 GPCRs, ion channels, and transporters at 
10 µM.  It was found to only significantly bind (>50%) to five receptors: adrenergic, α1A (77%); 
histamine, H1 (93%); sigma, σ1 (99%); dopamine transporter, DAT (72%); and norepinephrine 
transporter, NET (68%).57 
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Table 2.10.  DMPK comparison of VU0469118 and VU0603865. 
 
 
 Due to its pharmacological profile and selectivity, VU0603865 was declared an MLPCN 
(Molecular Libraries Probe Production Centers Network) probe, ML398.57  As ML398 is a potent, 
selective, and brain penetrant D4 antagonist, we wanted to test its ability to reverse 
hyperlocomotion induced by cocaine.  Figure 2.9 shows the results of this test using both 
VU0469118 and ML398.  Locomotion was measured by the number of laser beam breaks per 
minute using the SmartFrame open field activity chamber.  Cocaine alone significantly increased 
activity in rats over vehicle.  Both compounds were dosed with cocaine at 3 mg/kg and 10 mg/kg.  
VU0469118 did not show a statistically significant reduction in hyperlocomotion up to 10 mg/kg.  
However, ML398 did significantly reverse cocaine-induced hyperlocomotion at 10 mg/kg.57 
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Figure 2.9.  Effects of VU0469118 and ML398 on reversing cocaine-induced hyperlocomotion 
in rats. 
 
 While this is exciting data for the development of an in vivo tool, there are still properties 
about this compound that could be improved.  Also, the development of a PET tracer would require 
a compound exhibiting much higher binding affinity.  To this end, further enantiopure methylene-
linked libraries were synthesized around the benzimidazole using the previously described 
enantioselective route (Scheme 2.1b).  Table 2.11 shows the results of these libraries. 
This study provided very interesting SAR data.  The naphthyl substitution lead to a 
compound with 1.3 nM binding affinity, the most potent to date for this project.  It was found that 
very small changes in the benzimidazole ring system caused complete loss of activity.  For 
example, methylation of one of the nitrogens (VU0651665) or replacement of one nitrogen with 
sulfur or oxygen (VU0651731, VU0651677) resulted in nearly inactive compounds.   
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Table 2.11.  Potency and binding affinity of benzimidazole library. 
 
 Selectivity data was obtained for the best three compounds from this library (Table 2.12).  
None of these three were completely selective over the other dopamine receptors as they all 
exhibited weak D3 activity.  However, they were still >100-fold selective over D3, with 
VU0651632 being 2,000-fold selective. 
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Table 2.12.  Selectivity data for VU0651632, VU0652020, and VU0651729. 
 
 
The pharmacokinetic properties of the four most potent compounds in the second 
benzimidazole library were determined (Table 2.13).  The hepatic clearance remained very high, 
almost hepatic blood flow.  Also, the fraction unbound and CYP450 enzyme inhibition were much 
worse than ML398.  These properties could be due to the higher lipophilicity of these compounds.  
Unfortunately, the DMPK properties of these compounds excludes them from further in vivo 
testing. 
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Table 2.13.  In vitro PK properties of the most potent benzimidazole substituents. 
 
Even with its poor DMPK properties, our most potent compound, VU0651632, is in the 
desired range of binding affinity for PET imaging.  The next goal for this project was to synthesize 
a compound with a functionality that could be labeled with fluorine-18 while lowering lipophilicity 
and maintaining binding affinity. 
 
2.4.2. Phenyl Derivatives 
 In order to study the SAR of the western phenyl portion of the hit (see Figure 2.6), a new 
route had to be devised for ease of derivitization.  Scheme 2.4 shows this new synthesis.  
Ethanolamine was alkylated under microwave conditions with naphthyl bromide.  Aminoalcohol 
2.14 was then utilized in an epoxide opening to provide the desired morpholine core as well as an 
oxazepane byproduct.  Incorporating the chiral epoxide sets the desired stereochemistry for this 
scaffold.  Primary alcohol 2.15 was oxidized using Dess–Martin Periodinane followed by a 
Seyferth–Gilbert homologation with the Ohira–Bestmann modification to provide terminal alkyne 
2.18.  Sonogashira coupling under microwave conditions provided the diversification point for the 
library.  Finally, hydrogenation yielded the desired phenyl derivatives. 
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Scheme 2.4.  Synthetic route toward western phenyl derivatives. 
 
 Due to the high lipophilicity of the naphthyl derivative, we were most interested in 
installing polar groups to help decrease log P.  Table 2.14 shows the library and binding data for 
these derivatives.  Various 2-fluoropyridines were synthesized in the hopes of becoming 
radioligands.  The Vanderbilt Institute of Imaging Science prefers to install fluorine-18 through an 
aromatic nucleophilic substitution reaction with a 2-chloropyridine.  These fluoro-pyridines 
unfortunately resulted in significant loss of binding affinity.  This SAR study revealed that ortho-
substituted polar groups are well tolerated and generally give binding affinities in the 16-40 nM 
range. 
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Table 2.14.  Binding affinities and potencies of western phenyl derivatives. 
 
 
 It was later found through the synthesis of ML398 using the route in Scheme 2.4 that the 
enantiopurity of this library was not known due to ee loss somewhere along the route.  While this 
library still contains useful data concerning SAR, the synthetic scheme must be evaluated for the 
loss of enantiopurity and the problem reactions must be fixed in order to continue the investigation 
of phenyl derivatives. 
 
2.5. Future Directions 
 There is ongoing effort in the lab to study the structure-activity relationship of this novel 
D4 antagonist.  More derivatives of the western phenyl ring are planned, including a matrix library 
with the best moieties found so far replacing the phenyl and benzimidazole.  When a suitable 2-
fluoropyridine analog is found, PET studies will commence to study the location of D4 receptors 
in the brain.   
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 There are also plans for variations of the core region of the morpholine antagonist (Figure 
2.10).  The oxazepane byproduct (2.16) formed in the route to the phenyl derivatives will be an 
interesting core change.  Also, replacing the oxygen in the morpholine ring with a gem di-fluoro 
group could provide potent analogs with novel intellectual property.   
 
 
Figure 2.10.  Ideas for core changes. 
 
 The synthesis of the oxazepane core will begin with the same epoxide opening previously 
shown (Scheme 2.5).  Displacement of the alcohol will be facilitated by the triflate with 
deprotonated phenylacetylene.  Simultaneous hydrogenation and hydrogenolysis will reduce the 
alkyne and remove the benzyl group.  Finally, the nitrogen can be alkylated with any benzyl 
substituent.  These analogs will be racemic; if there are a few worth pursuing, the enantiomers will 
be resolved by supercritical fluid chromatography (SFC).  This scaffold is slightly different than 
the compounds reported by Audouze et al.; while their compounds were 2,4-disubstitued 
oxazepanes, these will be 3,5-disubstitued.44   
 
Scheme 2.5.  Planned synthesis of oxazepane core. 
 
 The synthesis of the di-fluoro piperidine begins with piperidinone 2.19 (Scheme 2.6).  
Alkylation of the nitrogen will be followed by addition of phenethyliodide.  The ester will be 
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removed under acidic conditions and DAST will be used to convert the ketone to a gem-di-fluoro 
group. 
 
Scheme 2.6.  Planned synthesis of the di-fluoro piperidine core. 
 
2.6. Conclusions 
 There is still much to be explored about the role of D4 receptors in various disease states.  
We hope to add to the limited knowledge by synthesizing a highly selective antagonist with low 
nanomolar binding affinity.  Our initial compound, VU0469118, already exhibited many of the 
properties needed for an in vivo probe and a PET tracer.  An initial SAR study identified ML398 
which has shown efficacy in the cocaine mechanism.  By further increasing the binding affinity 
while maintaining other important pharmacokinetic characteristics, we hope to find a candidate 
that can be used as an in vivo tool and a PET tracer to study cocaine addiction and its symptoms.    
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2.7. Experimental Methods 
All reagents and solvents were commercial grade and purified prior to use when necessary. 
Analytical thin layer chromatography (TLC) was performed on Sorbent Technologies HL 0.25 
mm silica gel plates with UV indicator. Visualization was accomplished by irradiation under a 254 
nm UV lamp and/or the use of an iodine chamber. Chromatography on silica gel was performed 
using Silica Gel 60 (230-400 mesh) from Sorbent Technologies.  1H and 13C NMR spectra were 
recorded on a Bruker DRX-400 (400 and 100 MHz, respectively) NMR instrument. Chemical 
shifts are reported in ppm from the solvent resonance as an internal standard. Data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad 
singlet), coupling constant (Hz), and number of protons.  Low resolution mass spectra were 
obtained on an Agilent 6130 Quadrupole LC/MS with electrospray ionization (RT = retention 
time).  Optical rotations were measured on a JASCO P-2000 digital polarimeter at room 
temperature. Concentration (c) in g/100 mL and solvent are given in parentheses.  Preparative 
purification was performed on a Gilson chromatograph using a Luna 5u C18(2) 100A AXIA 
column (30x50 mm) using a water/acetonitrile gradient.  Chiral separations were performed on a 
Thar Investigator II supercritical fluid chromatograph (SFC) using Lux Cellulose 4 (10x250 mm), 
Chiralpak IA (10x250 mm), and Chiralpak ID (10x250 mm) columns.  A Micromass Q-Tof API-
US mass spectrometer was used to acquire high resolution mass spectrometry (HRMS) data. The 
value Δ is the error in the measurement (in ppm) given by the equation Δ = [(ME – MT)/ MT] × 
106, where ME is the experimental mass and MT is the theoretical mass. The HRMS results were 
obtained with ES as the ion source and leucine enkephalin as the reference. 
 
 
2.8 
(S)-2-chloro-4-phenylbutan-1-ol (2.8).  Suspended 4-phenylbutanal (147 mg, 0.992 mmol) in 
anhydrous dichloromethane (4.0 mL) and cooled to 0 °C.  (2R,5R)-Diphenylpyrrolidine (22.0 mg, 
0.099 mmol) added followed by N-chlorosuccinimide (172 mg, 1.29 mmol).  The progress of this 
reaction was monitored by proton NMR (the starting material aldehyde peak being converted to 
the mono-chlorinated aldehyde).  Once complete, methanol (4.0 mL) was added at 0 °C followed 
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by the slow addition of sodium borohydride (187 mg, 4.96 mmol).  Continued stirring for 30 
minutes before water was added and the solution was extracted with dichloromethane.  After 
drying over sodium sulfate, filtering, and concentrating, the crude material was purified by column 
chromatography (0-45% ethyl acetate in hexanes).  Pure chloro-alcohol was collected (158 mg, 
86%) in 93% ee. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.99-2.09 (m, 3H), 2.73-2.80 (m, 1H), 2.87-2.94 (m, 1H), 
3.67-3.82 (m, 2H), 3.96-4.02 (m, 1H), 7.20-7.33 (m, 5H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
32.3, 35.8, 64.0, 66.9, 126.2, 128.4, 128.5, 140.6.  [α]D20 = -48.4 (c = 1.0, CH3OH).  Spectral data 
matches that recorded by M. O’Reilly and C. Lindsley, Organic Letters, 14, 2910.  
 
 
2.9 
(S)-2-(benzyl(2-chloro-4-phenylbutyl)amino)ethanol (2.9).  (S)-2-chloro-4-phenylbutan-1-ol 
(0.530 g, 2.87 mmol) was suspended in anhydrous dichloromethane (28.0 mL) and to this 2,6-
lutidine (3.3 mL, 28.7 mmol) was added.  This solution was cooled to -78 °C before triflic 
anhydride (0.63 mL, 3.73 mmol) was added dropwise.  This was stirred 30 minutes and the triflate 
was confirmed to be formed by proton NMR.  N-benzylethanolamine (2.1 mL, 14.3 mmol) in 
anhydrous dichloromethane (2.0 mL) was added to the solution dropwise.  The reaction was 
allowed to warm to room temperature slowly overnight and the consumption of the triflate was 
established by NMR.  Diethyl ether (100 mL) and water (100 mL) was added and the organic layer 
was separated from the aqueous, dried over sodium sulfate, filtered, and concentrated in vacuo.  
The crude product was purified by column chromatography (0-20% ethyl acetate in hexanes) to 
yield the chloro-aminoalcohol (0.715 g, 78%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.88-1.99 (m, 1H), 2.07-2.18 (m, 1H), 2.63-2.96 (m, 7H), 
3.53-3.76 (m, 4H), 3.90-3.99 (m, 1H), 7.20-7.40 (m, 10H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
32.3, 37.6, 56.3, 58.8, 59.3, 60.3, 61.1, 126.1, 127.4, 128.4, 128.5, 128.5, 129.0, 138.2, 140.8.  
LCMS:  RT 0.892 min, m/z = 319.9 [M+H]
+, >99% @ 215 nm.  [α]D20 = -15.1 (c = 1.0, CH3OH).  
Spectral data matches that recorded by M. O’Reilly and C. Lindsley, Organic Letters, 14, 2910.  
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2.10 
(R)-4-benzyl-2-phenethylmorpholine (2.10).  Suspended (S)-2-(benzyl(2-chloro-4-phenylbutyl) 
amino)ethanol (0.660 g, 2.08 mmol) in anhydrous acetonitrile (100 mL) and cooled to -20 °C.  
Potassium tert-butoxide (1.17 g, 10.4 mmol) was added and the progress of the reaction was 
followed by TLC.  Upon consumption of starting material, water and diethyl ether were added to 
the reaction and it was extracted with ether, dried over sodium sulfate, filtered, and concentrated.  
The crude material was purified by column chromatography (0-40% ethyl acetate in hexanes) to 
give the morpholine (0.316 g, 54%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.63-1.74 (m, 1H), 1.78-1.89 (m, 1H), 1.92 (t, J = 10.7 Hz, 
1H), 2.21 (td, J = 3.2, 11.1 Hz, 1H), 2.63-2.86 (m, 4H), 3.50-3.58 (m, 3H), 3.70 (td, J = 2.4, 11.1 
Hz, 1H), 3.92 (d, J = 11.1 Hz, 1H), 7.18-7.24 (m, 3H), 7.25-7.39 (m, 7H).  13C NMR (CDCl3, 100 
MHz) δ (ppm): 31.5, 35.3, 53.2, 58.6, 63.3, 66.7, 74.8, 125.7, 127.1, 128.2, 128.3, 128.4, 129.1, 
137.7, 142.0.  LCMS:  RT 0.924 min, m/z = 282.0 [M+H]
+, >99% @ 215 nm.  [α]D20 = +30.3 (c = 
1.0, CH3OH).  Spectral data matches that recorded by M. O’Reilly and C. Lindsley, Organic 
Letters, 14, 2910. 
 
 
(R)-2.3 
(R)-2-phenethylmorpholine ((R)-2.3).  Suspended (R)-4-benzyl-2-phenethylmorpholine (88.0 
mg, 0.313 mmol) in anhydrous methanol (6.3 mL).  The flask was purged three times alternating 
vacuum and argon.  To this was added 10% Pd/C (6.6 mg, 0.063 mmol) and the flask was purged 
three times alternating vacuum and hydrogen gas.  The reaction was followed by TLC and LCMS 
until it was complete.  The solution was then filtered through celite with methanol, concentrated, 
and carried on crude.   
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(R)-2.5, VU0469118 
(R)-4-((1H-benzo[d]imidazol-2-yl)methyl)-2-phenethylmorpholine (VU0469118).   
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.53-1.63 (m, 1H), 1.73-1.84 (m, 1H), 2.04 (J = 10.28, 1H), 
2.34 (td, J = 3.4, 11.6 Hz, 1H), 2.56-2.78 (m, 4H), 3.42-3.44 (m, 1H), 3.67 (td, J = 2.1, 11.6 Hz, 
1H), 3.77-3.90 (m, 3H), 7.12-7.21 (m, 3H), 7.23-7.31 (m, 4H), 7.62 (bs, 2H).  13C NMR (CDCl3, 
100 MHz) δ (ppm): 31.4, 35.0, 53.4, 56.6, 58.7, 66.5, 74.7, 114.9, 122.4, 125.8, 128.4 (2C), 138.7, 
141.7, 151.8.  [α]D20 = +38.3 (c = 1.0, CH3OH).  Spectral data matches that recorded by M. 
O’Reilly and C. Lindsley.  
 
 
ML398 
(R)-4-(4-chlorobenzyl)-2-phenethylmorpholine (VU0603865, ML398).  In a microwave vial, 
suspended (R)-2-phenethylmorpholine (0.100 g, 0.523 mmol) in anhydrous acetonitrile (2.6 mL).  
Potassium carbonate (0.361 g, 2.61 mmol) and 4-chlorobenzyl bromide (0.107 g, 0.523 mmol) 
were added.  This was heated under microwave conditions to 120 °C for ten minutes.  Water was 
added and the product was extracted with ethyl acetate.  The organic layer was dried over sodium 
sulfate, filtered, and concentrated in vacuo.  The crude material was purified by column 
chromatography (0-30% ethyl acetate in hexanes) to provide pure product (0.103 mg, 61%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.73 (dm, J = 64 Hz, 2H), 1.88 (t, J = 10.4 Hz, 1H), 2.20 
(dt, J = 3.1, 11.5 Hz, 1H), 2.59-2.71 (m, 3H), 2.73-2.84 (m, 1H), 3.45 (s, 2H), 3.45-3.53 (m, 1H), 
3.65 (t, J = 11.3 Hz, 1H), 3.89 (d, J = 11.5 Hz, 1H), 7.15-7.22 (m, 3H), 7.23-7.32 (m, 6H).  13C 
NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 53.1, 58.5, 62.4, 66.6, 74.8, 125.7, 128.3 (2C), 
128.4, 130.3, 132.8, 136.3, 141.9.  LCMS:  RT 0.850 min, m/z = 316.9 [M+H]
+, >99% @ 215 and 
254 nm.  HRMS: C19H23NOCl, Calculated [M+H]
+: 316.1468, Found [M+H]+: 316.1470.  [α]D20 
= +29.3 (c = 1.0, CH3OH, 92% ee). 
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(R)-4-(4-methoxybenzyl)-2-phenethylmorpholine (VU0603864). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.58-1.71 (m, 1H), 1.75-1.91 (m, 2H), 2.15 (dt, J = 3.3, 
11.4 Hz, 1H), 2.60-2.82 (m, 4H), 3.43 (s, 2H), 3.45-3.54 (m, 1H), 3.65 (dt, J = 2.4, 11.3 Hz, 1H), 
3.81 (s, 3H), 3.88 (dm, J = 11.3 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 7.15-7.30 (m, 7H).  13C NMR 
(CDCl3, 100 MHz) δ (ppm): 31.5, 35.3, 53.1, 55.2, 58.5, 62.6, 66.7, 74.8, 113.5, 125.7, 128.3, 
128.4, 129.7, 130.3, 142.0, 158.7.  LCMS:  RT 0.852 min, m/z = 312.0 [M+H]
+, >99% @ 215 and 
254 nm.  HRMS: C20H26NO2, Calculated [M+H]
+: 312.1964, Found [M+H]+: 312.1964.  [α]D20 = 
+44.4 (c = 0.33, CH3OH, 92% ee). 
 
 
(R)-2-phenethyl-4-(4-(trifluoromethoxy)benzyl)morpholine (VU0603764). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.61-1.87 (m, 2H), 1.91 (t, J = 11.0 Hz, 1H), 2.19 (dt, J = 
3.3, 11.3 Hz, 1H), 2.60-2.73 (m, 3H), 2.74-2.84 (m, 1H), 3.46 (s, 2H), 3.46-3.55 (m, 1H), 3.67 (dt, 
J = 2.4, 11.4 Hz, 1H), 3.87-3.93 (m, 1H), 7.14-7.23 (m, 5H), 7.25-7.31 (m, 2H), 7.32-7.38 (m, 
2H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 53.1, 58.6, 62.3, 66.7, 74.8, 120.7, 125.7, 
128.3, 128.4, 130.2, 136.6, 141.9, 148.2.  LCMS:  RT 0.997 min, m/z = 365.9 [M+H]
+, >99% @ 
215 and 254 nm.  HRMS: C20H23NO2F3, Calculated [M+H]
+: 366.1681, Found [M+H]+: 366.1679.  
[α]D20 = +22.6 (c = 1.0, CH3OH, 92% ee). 
 
 
2.11 
2-chloro-4-phenylbutan-1-ol (2.11).  Suspended 4-phenylbutanal (1.16 g, 7.83 mmol) in 
anhydrous dichloromethane (31.0 mL) and cooled to 0 °C.  DL-proline (180 mg, 1.56 mmol) was 
added followed by N-chlorosuccinimide (1.36 g, 10.2 mmol).  The progress of this reaction was 
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monitored by proton NMR (the starting material aldehyde peak being converted to the mono-
chlorinated aldehyde).  Once complete, methanol (31.0 mL) was added at 0 °C followed by slow 
addition of sodium borohydride (1.48 g, 39.1 mmol).  Continued stirring for 30 minutes before 
water was added and the solution was extracted with dichloromethane.  After drying over sodium 
sulfate, filtering, and concentrating, the crude material was purified by column chromatography 
(0-45% ethyl acetate in hexanes).  Pure racemic chloro-alcohol was collected (1.10 g, 76%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.99-2.09 (m, 3H), 2.73-2.80 (m, 1H), 2.87-2.94 (m, 1H), 
3.67-3.82 (m, 2H), 3.96-4.02 (m, 1H), 7.20-7.33 (m, 5H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
32.3, 35.8, 64.0, 66.9, 126.2, 128.4, 128.5, 140.6.     
 
 
2.12 
2-(benzyl(2-chloro-4-phenylbutyl)amino)ethanol (2.12).  2-chloro-4-phenylbutan-1-ol (0.537 g, 
2.91 mmol) was suspended in anhydrous dichloromethane (29.0 mL) and to this 2,6-lutidine (3.37 
mL, 29.1 mmol) was added.  This solution was cooled to -78 °C before triflic anhydride (0.63 mL, 
3.78 mmol) was added dropwise.  This was stirred 30 minutes and the triflate was confirmed to be 
formed by proton NMR.  N-benzylethanolamine (2.1 mL, 14.5 mmol) in anhydrous 
dichloromethane (2.0 mL) was added to the solution dropwise.  The reaction was allowed to warm 
to room temperature slowly overnight and the consumption of the triflate was established by NMR.  
Diethyl ether (100 mL) and water (100 mL) was added and the organic layer was separated from 
the aqueous, dried over sodium sulfate, filtered, and concentrated in vacuo.  The crude product 
was purified by column chromatography (0-20% ethyl acetate in hexanes) to yield the racemic 
chloro-aminoalcohol (0.718 g, 78%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.88-1.99 (m, 1H), 2.07-2.18 (m, 1H), 2.63-2.96 (m, 7H), 
3.53-3.76 (m, 4H), 3.90-3.99 (m, 1H), 7.20-7.40 (m, 10H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
32.3, 37.6, 56.3, 58.8, 59.3, 60.3, 61.1, 126.1, 127.4, 128.4, 128.5, 128.5, 129.0, 138.2, 140.8.  
LCMS:  RT 0.892 min, m/z = 319.9 [M+H]
+, >99% @ 215 nm.   
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2.13 
4-benzyl-2-phenethylmorpholine (2.13, VU0517051).  Suspended 2-(benzyl(2-chloro-4-
phenylbutyl) amino)ethanol (0.650 g, 2.05 mmol) in anhydrous acetonitrile (100 mL) and cooled 
to -20 °C.  Potassium tert-butoxide (1.15 g, 10.2 mmol) was added and the progress of the reaction 
was followed by TLC.  Upon consumption of starting material, water and diethyl ether were added 
to the reaction and it was extracted with ether, dried over sodium sulfate, filtered, and concentrated.  
The crude material was purified by column chromatography (0-40% ethyl acetate in hexanes) to 
give the racemic morpholine (0.316 g, 55%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.63-1.74 (m, 1H), 1.78-1.89 (m, 1H), 1.92 (t, J = 10.7 Hz, 
1H), 2.21 (td, J = 3.2, 11.1 Hz, 1H), 2.63-2.86 (m, 4H), 3.50-3.58 (m, 3H), 3.70 (td, J = 2.4, 11.1 
Hz, 1H), 3.92 (d, J = 11.1 Hz, 1H), 7.18-7.24 (m, 3H), 7.25-7.39 (m, 7H).  13C NMR (CDCl3, 100 
MHz) δ (ppm): 31.5, 35.3, 53.2, 58.6, 63.3, 66.7, 74.8, 125.7, 127.1, 128.2, 128.3, 128.4, 129.1, 
137.7, 142.0.  LCMS:  RT 0.924 min, m/z = 282.0 [M+H]
+, >99% @ 215 nm.   
   
 
2.3 
2-phenethylmorpholine (2.3).  Suspended 4-benzyl-2-phenethylmorpholine (200 mg, 0.711 
mmol) in anhydrous methanol (10.0 mL).  The flask was purged three times alternating vacuum 
and argon.  Added to this was 10% Pd/C (15.1 mg, 0.142 mmol) and the flask was purged three 
times alternating vacuum and hydrogen gas.  The reaction was followed by TLC and LCMS until 
it was complete.  The solution was then filtered through celite with methanol, concentrated, and 
carried on crude. 
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General procedure for N-alkylation: 
2-phenethylmorpholine (7.5 mg, 0.04 mmol) was suspended in N,N-dimethylformamide (0.50 
mL).  To this was added Hunig’s base (34 µL, 0.19 mmol) and the desired benzyl halide (0.05 
mmol).  The reaction was stirred at 40 °C for 30 minutes before being purified by automated 
reverse phase column chromatography. 
 
 
2-phenethyl-4-(3-(trifluoromethoxy)benzyl)morpholine (VU0517381). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.86 (m, 2H), 1.86-2.00 (m, 1H), 2.13-2.28 (m, 1H), 
2.58-2.84 (m, 4H), 3.50 (bs, 2H), 3.60-3.76 (m, 1H), 3.84-3.94 (m, 1H), 7.09-7.14 (m, 1H), 7.14-
7.23 (m, 4H), 7.23-7.29 (m, 3H), 7.30-7.37 (m, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 
35.2, 52.9, 58.3, 62.4, 66.4, 74.7, 119.1, 119.6, 121.4, 125.7, 127.3, 128.3 (2C), 129.6, 141.8, 
149.3.  LCMS:  RT 0.987 min, m/z = 365.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
4-(2,6-difluorobenzyl)-2-phenethylmorpholine (VU0517302). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.86 (m, 2H), 1.93-2.06 (m, 1H), 2.22-2.35 (m, 1H), 
2.59-2.84 (m, 4H), 3.50 (bs, 1H), 3.59-3.78 (m, 3H), 3.84-3.94 (m, 1H), 6.86-6.94 (m, 2H), 7.14-
7.20 (m, 3H), 7.22-7.30 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.3, 48.7, 52.0, 
57.5, 66.5, 74.7, 111.0, 111.2, 125.7, 128.3, 128.4, 129.5, 141.9, 160.7, 160.8, 163.2 (2C).  LCMS:  
RT 0.880 min, m/z = 317.9 [M+H]
+, >99% @ 215 and 254 nm. 
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4-(4-fluorobenzyl)-2-phenethylmorpholine (VU0517120). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.85 (m, 2H), 1.85-1.94 (m, 1H), 2.13-2.24 (m, 1H), 
2.60-2.73 (m, 3H), 2.73-2.83 (m, 1H), 3.46 (s, 2H), 3.48-3.56 (m, 1H), 3.61-3.73 (m, 1H), 3.86-
3.93 (m, 1H), 7.01 (t, J = 8.6 Hz, 1H), 7.15-7.21 (m, 3H), 7.24-7.32 (m, 4H).  13C NMR (CDCl3, 
100 MHz) δ (ppm): 31.5, 35.3, 53.0, 58.4, 62.4, 66.6, 74.8, 114.9, 115.1, 125.7, 128.3, 128.4, 
130.5, 130.6, 141.9.  LCMS:  RT 0.842 min, m/z = 300.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
4-(2-methylbenzyl)-2-phenethylmorpholine (VU0517380). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.86 (m, 2H), 1.90-2.00 (m, 1H), 2.10-2.30 (m, 1H), 
2.36 (s, 3H), 2.57-2.73 (m, 3H), 2.72-2.83 (m, 1H), 3.44 (bs, 2H), 3.56-3.70 (m, 1H), 3.84-3.90 
(m, 1H), 7.11-7.20 (m, 6H), 7.22-7.29 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 19.2, 31.6, 
35.3, 53.2, 58.6, 61.1, 66.8, 74.9, 125.4, 125.7, 127.1, 128.3, 128.4, 129.8, 130.2, 137.5, 142.0.  
LCMS:  RT 0.946 min, m/z = 296.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-4-(pyridin-2-ylmethyl)morpholine (VU0517003). 
LCMS:  RT 0.744 min, m/z = 283.1 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-4-(pyridin-3-ylmethyl)morpholine (VU0517029). 
LCMS:  RT 0.610 min, m/z = 283.0 [M+H]
+, >99% @ 215 and 254 nm. 
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2-phenethyl-4-(pyridin-4-ylmethyl)morpholine (VU0517301). 
LCMS:  RT 0.675 min, m/z = 283.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
General procedure for amide synthesis: 
2-phenethylmorpholine (7.5 mg, 0.04 mmol) was suspended in N,N-dimethylformamide (0.50 
mL).  To this was added Hunig’s base (34 µL, 0.19 mmol) and the desired acid chloride (0.05 
mmol).  The reaction was stirred at room temperature for one hour before being purified by 
automated reverse phase column chromatography. 
 
 
(2-phenethylmorpholino)(p-tolyl)methanone (VU0517002). 
LCMS:  RT 1.128 min, m/z = 310.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(4-chlorophenyl)(2-phenethylmorpholino)methanone (VU0517030). 
LCMS:  RT 1.142 min, m/z = 330.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(2-phenethylmorpholino)(phenyl)methanone (VU0517052). 
LCMS:  RT 1.072 min, m/z = 296.0 [M+H]
+, >99% @ 215 and 254 nm. 
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(2-phenethylmorpholino)(pyridin-3-yl)methanone (VU0517053). 
LCMS:  RT 0.813 min, m/z = 296.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(4-methoxyphenyl)(2-phenethylmorpholino)methanone (VU0517134). 
LCMS:  RT 1.074 min, m/z = 326.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
Isoxazol-5-yl(2-phenethylmorpholino)methanone (VU0517298). 
LCMS:  RT 0.992 min, m/z = 286.9 [M+H]
+, >92% @ 215 nm. 
 
 
Mesityl(2-phenethylmorpholino)methanone (VU0517299). 
LCMS:  RT 1.207 min, m/z = 338.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(3-fluorophenyl)(2-phenethylmorpholino)methanone (VU0517300). 
LCMS:  RT 1.104 min, m/z = 313.9 [M+H]
+, >94% @ 215 nm. 
 
92 
 
 
(2-phenethylmorpholino)(3,4,5-trifluorophenyl)methanone (VU0517354). 
LCMS:  RT 1.163 min, m/z = 349.9 [M+H]
+, >97% @ 215 nm. 
 
 
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(2-phenethylmorpholino)methanone (VU0517379). 
LCMS:  RT 1.074 min, m/z = 353.9 [M+H]
+, >96% @ 215 nm. 
 
 
(2-phenethylmorpholino)(quinolin-2-yl)methanone (VU0517523). 
LCMS:  RT 1.118 min, m/z = 346.9 [M+H]
+, >95% @ 215 nm. 
 
General procedure for Buchwald–Hartwig coupling: 
2-phenethylmorpholine (7.5 mg, 0.04 mmol) was suspended in 1,4-dioxane (0.50 mL).  To this 
was added tris(dibenzylideneacetone)dipalladium(0) (1.8 mg, 0.002 mmol), 4,5-
bis(diphenylphosphino)-9,9-dimethylxanthene (2.3 mg, 0.004 mmol), cesium carbonate (32 mg, 
0.10 mmol), and the desired aryl bromide (0.033 mmol).  The reaction was stirred under argon at 
100 °C for 18 hours.  When complete, the reaction was quenched with water and extracted with 
ethyl acetate before being purified by automated reverse phase column chromatography. 
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2-phenethyl-4-phenylmorpholine (VU0517240). 
LCMS:  RT 1.177 min, m/z = 268.0 [M+H]
+, >95% @ 215 nm. 
 
 
4-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-phenethylmorpholine (VU0517535). 
LCMS:  RT 0.931 min, m/z = 322.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-4-(p-tolyl)morpholine (VU0517595). 
LCMS:  RT 1.117 min, m/z = 282.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-4-(quinolin-6-yl)morpholine (VU0517596). 
LCMS:  RT 0.961 min, m/z = 319.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
General procedure for urea synthesis: 
2-phenethylmorpholine (7.5 mg, 0.04 mmol) was suspended in tetrahydrofuran (0.50 mL).  To this 
was added the desired aryl isocyanate (0.05 mmol).  The reaction was stirred at room temperature 
for one hour before being purified by automated reverse phase column chromatography. 
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2-phenethyl-N-phenylmorpholine-4-carboxamide (VU0517262). 
LCMS:  RT 1.127 min, m/z = 311.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
N-(4-methoxyphenyl)-2-phenethylmorpholine-4-carboxamide (VU0517319). 
LCMS:  RT 1.098 min, m/z = 340.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
N-(2-chlorophenyl)-2-phenethylmorpholine-4-carboxamide (VU0517320). 
LCMS:  RT 1.185 min, m/z = 345.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
N-(4-fluorophenyl)-2-phenethylmorpholine-4-carboxamide (VU0517328). 
LCMS:  RT 1.127 min, m/z = 328.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-N-(p-tolyl)morpholine-4-carboxamide (VU0517347). 
LCMS:  RT 1.150 min, m/z = 325.0 [M+H]
+, >99% @ 215 and 254 nm. 
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N-(3-fluorophenyl)-2-phenethylmorpholine-4-carboxamide (VU0517348). 
LCMS:  RT 1.151 min, m/z = 328.9 [M+H]
+, >95% @ 215 nm. 
 
 
N-(2-fluorophenyl)-2-phenethylmorpholine-4-carboxamide (VU0517572). 
LCMS:  RT 1.107 min, m/z = 328.9 [M+H]
+, >94% @ 215 nm. 
 
 
N-(4-chlorophenyl)-2-phenethylmorpholine-4-carboxamide (VU0517647). 
LCMS:  RT 1.181 min, m/z = 345.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-N-(o-tolyl)morpholine-4-carboxamide (VU0517574). 
LCMS:  RT 1.107 min, m/z = 325.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
General procedure for sulfonamide synthesis: 
2-phenethylmorpholine (7.5 mg, 0.04 mmol) was suspended in N,N-dimethylformamide (0.50 
mL).  To this was added Hunig’s base (34 µL, 0.19 mmol) and the desired sulfonyl chloride (0.05 
mmol).  The reaction was stirred at 40 °C for one hour before being purified by automated reverse 
phase column chromatography. 
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4-(naphthalen-2-ylsulfonyl)-2-phenethylmorpholine (VU0517473). 
LCMS:  RT 1.236 min, m/z = 382.1 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
2-phenethyl-4-((2-(trifluoromethoxy)phenyl)sulfonyl)morpholine (VU0517474). 
LCMS:  RT 1.292 min, m/z = 415.8 [M+H]
+, >95% @ 215 nm. 
 
 
4-((2-fluorophenyl)sulfonyl)-2-phenethylmorpholine (VU0517475). 
LCMS:  RT 1.206 min, m/z = 349.9 [M+H]
+, >95% @ 215 nm. 
 
 
2-phenethyl-4-(m-tolylsulfonyl)morpholine (VU0517476). 
LCMS:  RT 1.247 min, m/z = 345.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
4-((2-chlorophenyl)sulfonyl)-2-phenethylmorpholine (VU0517550). 
LCMS:  RT 1.233 min, m/z = 366.8 [M+H]
+, >99% @ 215 and 254 nm. 
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4-((4-fluorophenyl)sulfonyl)-2-phenethylmorpholine (VU0517570). 
LCMS:  RT 1.216 min, m/z = 349.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
4-((4-(tert-butyl)phenyl)sulfonyl)-2-phenethylmorpholine (VU0517594). 
LCMS:  RT 1.372 min, m/z = 387.9 [M+H]
+, >95% @ 215 nm. 
 
 
4-((3-fluorophenyl)sulfonyl)-2-phenethylmorpholine (VU0517651). 
LCMS:  RT 1.221 min, m/z = 349.9 [M+H]
+, >95% @ 215 nm. 
 
 
2-phenethyl-4-(phenylsulfonyl)morpholine (VU0517653). 
LCMS:  RT 1.131 min, m/z = 332.1 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-2-phenethyl-4-(quinolin-2-ylmethyl)morpholine (VU0651729). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.88 (m, 2H), 2.04-2.16 (m, 1H), 2.34-2.46 (m, 1H), 
2.60-2.70 (m, 1H), 2.71-2.83 (m, 3H), 3.58 (bs, 1H), 3.69-3.80 (m, 1H), 3.85 (s, 2H), 3.88-3.95 
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(m, 1H), 7.14-7.19 (m, 3H), 7.23-7.29 (m, 2H), 7.50-7.56 (m, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.68-
7.74 (m, 1H), 7.81 (d, J = 8.1 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H).  13C 
NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 53.3, 58.7, 65.3, 66.6, 74.8, 121.1, 125.7, 126.2, 
127.4, 127.5, 128.3, 128.4, 129.0, 129.4, 136.4, 141.9, 147.6.  LCMS:  RT 0.929 min, m/z = 333.0 
[M+H]+, >91% @ 215 nm.  HRMS: C22H25N2O, Calculated [M+H]
+: 333.1967, Found [M+H]+: 
333.1966.  [α]D20 = +19.9 (c = 1.0, CH3OH, 92% ee). 
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-phenethylmorpholine (VU0651632). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.51-1.79 (m, 2H), 1.82-1.96 (m, 1H), 2.10-2.25 (m, 1H), 
2.50-2.61 (m, 1H), 2.61-2.77 (m, 3H), 3.46 (bs, 1H), 3.52-3.72 (m, 3H), 3.78-3.87 (m, 1H), 7.06-
7.11 (m, 3H), 7.14-7.20 (m, 2H), 7.35-7.46 (m, 3H), 7.66 (s, 1H), 7.70-7.78 (m, 3H).  13C NMR 
(CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 53.1, 58.3, 63.2, 66.4, 74.6, 125.7, 125.8, 126.0, 127.4, 
127.6, 127.7, 128.0, 128.3, 128.4, 132.8, 133.2, 141.8.  LCMS:  RT 0.933 min, m/z = 331.9 
[M+H]+, >99% @ 215 and 254 nm.  HRMS: C23H26NO, Calculated [M+H]
+: 332.2014, Found 
[M+H]+: 332.2017.  [α]D20 = +24.8 (c = 1.0, CH3OH, 92% ee). 
 
 
(R)-4-(3-fluoro-4-methoxybenzyl)-2-phenethylmorpholine (VU0652020). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.52-1.78 (m, 2H), 1.79 (t, J = 10.5 Hz, 1H), 2.08 (dt, J = 
3.0, 11.4 Hz, 1H), 2.51-2.64 (m, 3H), 2.65-2.74 (m, 1H), 3.33 (s, 2H), 3.38-3.47 (m, 1H), 3.54-
3.63 (m, 1H), 3.77-3.84 (m, 4H), 6.81 (t, J = 8.4 Hz, 1H), 6.88-6.94 (m, 1H), 7.00 (dd, J = 1.9, 
12.2 Hz, 1H), 7.07-7.13 (m, 3H), 7.16-7.22 (m, 2H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 
35.3, 53.0, 56.2, 58.4, 62.2, 66.6, 74.8, 113.0, 116.6, 116.7, 124.6, 125.7, 128.3, 128.4, 141.9, 
151.0, 153.5.  LCMS:  RT 0.825 min, m/z = 330.0 [M+H]
+, >99% @ 215 and 254 nm.  HRMS: 
C20H25NO2F, Calculated [M+H]
+: 330.1869, Found [M+H]+: 330.1870.  [α]D20 = +26.8 (c = 1.0, 
CH3OH, 92% ee). 
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(2R)-4-(1-(1H-benzo[d]imidazole-2-yl)ethyl)-2-phenethylmorpholine (VU0651634). 
Mixture of diastereomers: 1H NMR (CDCl3, 400 MHz) δ (ppm): 1.54 (s, 3H), 1.56 (s, 3H), 1.60-
1.73 (m, 2H), 1.76-1.89 (m, 2H), 2.14 (t, J = 10.6 Hz, 1H), 2.30 (t, J = 10.6 Hz, 1H), 2.43 (dt, J = 
3.0, 11.5 Hz, 1H), 2.58-2.71 (m, 6H), 2.71-2.81 (m, 2H), 3.46-3.58 (m, 2H), 3.64-3.77 (m, 2H), 
3.90-4.04 (m, 3H), 7.13-7.21 (m, 5H), 7.23-7.29 (m, 4H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
13.4, 14.0, 31.3, 31.4, 34.9, 35.1, 47.9, 51.6, 52.9, 57.1, 59.2, 59.4, 66.6, 74.8 (2C), 125.8, 128.3, 
128.4, 141.6.  LCMS:  RT 0.868 min, m/z = 336.0 [M+H]
+, >99% @ 215 and 254 nm.  HRMS: 
C21H25N3O, Calculated [M+H]
+: 335.1998, Found [M+H]+: 335.2001. 
 
 
(R)-4-(benzo[d]thiazol-2-ylmethyl)-2-phenethylmorpholine (VU0651731). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.63-1.90 (m, 2H), 2.11-2.25 (m, 1H), 2.40-2.55 (m, 1H), 
2.61-2.82 (m, 2H), 2.82-2.94 (m, 2H), 3.60 (bs, 1H), 3.70-3.83 (m, 1H), 3.90-4.05 (m, 3H), 7.15-
7.21 (m, 3H), 7.24-7.30 (m, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.88 (d, J = 7.9 
Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.1, 53.2, 58.5, 
60.3, 66.5, 74.8, 121.7, 122.8, 124.9, 125.8, 125.9, 128.3, 128.4, 135.4, 141.8, 153.2.  LCMS:  RT 
0.933 min, m/z = 339.0 [M+H]+, >99% @ 215 and 254 nm.  HRMS: C20H22N2OS, Calculated 
[M+H]+: 338.1453, Found [M+H]+: 338.1457.  [α]D20 = +40.05 (c = 0.5, CH3OH). 
 
 
(R)-2-((2-phenthylmorpholino)methyl)benzo[d]oxazole (VU0651677). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.62-1.88 (m, 2H), 2.11-2.26 (m, 1H), 2.40-2.56 (m, 1H), 
2.60-2.83 (m, 2H), 2.87 (d, J = 10.2 Hz, 2H), 3.62 (bs, 1H), 3.71-3.84 (m, 1H), 3.85-3.98 (m, 3H), 
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7.13-7.20 (m, 3H), 7.22-7.29 (m, 1H), 7.32-7.39 (m, 2H), 7.52-7.58 (m, 1H), 7.70-7.76 (m, 1H).  
13C NMR (CDCl3, 100 MHz) δ (ppm): 31.4, 35.1, 52.8, 55.3, 58.2, 66.3, 74.5, 110.7, 120.71, 
124.4, 125.2, 125.8, 128.3, 128.4, 140.8, 141.7, 150.9.  LCMS:  RT 0.904 min, m/z = 323.0 
[M+H]+, >99% @ 215 and 254 nm.  HRMS: C20H22N2O2, Calculated [M+H]
+: 322.1681, Found 
[M+H]+: 322.1687.  [α]D20 = +19.8 (c = 0.5, CH3OH). 
 
 
(R)-4-(isoquinolin-3-ylmethyl)-2-phenethylmorpholine (VU0651675). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.88 (m, 2H), 2.07-2.20 (m, 1H), 2.36-2.49 (m, 1H), 
2.56-2.70 (m, 1H), 2.72-2.85 (m, 3H), 3.65 (bs, 1H), 3.71-3.82 (m, 1H), 3.83-3.95 (m, 3H), 7.14-
7.19 (m, 3H), 7.23-7.28 (m, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.62-7.68 (m, 1H), 7.69-7.74 (m, 1H), 
7.82 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H).  13C NMR (CDCl3, 
100 MHz) δ (ppm): 31.4, 35.2, 53.3, 58.6, 65.2, 66.5, 74.7, 121.2, 125.7, 126.3, 127.4, 127.5, 
128.3, 128.4, 129.0, 129.4, 136.5, 141.8, 147.6.  LCMS:  RT 0.880 min, m/z = 333.0 [M+H]
+, 
>99% @ 215 and 254 nm.  HRMS: C22H24N2O, Calculated [M+H]
+: 332.1889, Found [M+H]+: 
332.1894.  [α]D20 = +21.1 (c = 0.1, CH3OH, 92% ee). 
 
 
(R)-4-(4-(methylthio)benzyl)-2-phenethylmorpholine (VU0651676). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.86 (m, 2H), 1.86-1.97 (m, 1H), 2.13-2.26 (m, 1H), 
2.49 (s, 3H), 2.59-2.83 (m, 4H), 3.41-3.60 (m, 3H), 3.62-3.75 (m, 1H), 3.89 (d, J = 11.4 Hz, 1H), 
7.14-7.30 (m, 9H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 15.9, 31.5, 35.3, 53.0, 58.4, 62.6, 66.5, 
74.7, 123.5, 125.7, 126.5, 128.3, 128.4, 129.7, 141.9.  LCMS:  RT 0.907 min, m/z = 327.9 [M+H]
+, 
>99% @ 215 and 254 nm.  HRMS: C20H25NOS, Calculated [M+H]
+: 327.1657, Found [M+H]+: 
327.1663.  [α]D20 = +29.1 (c = 0.5, CH3OH, 92% ee). 
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(R)-4-(4-(methylsulfonyl)benzyl)-2-phenethylmorpholine (VU0651733). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.87 (m, 2H), 1.90-2.01 (m, 1H), 2.19-2.31 (m, 1H), 
2.60-2.73 (m, 3H), 2.73-2.84 (m, 1H), 3.06 (s, 3H), 3.47-3.64 (m, 3H), 3.64-3.76 (m, 1H), 3.91 (d, 
J = 11.3 Hz, 1H), 7.14-7.22 (m, 3H), 7.24-7.31 (m, 2H), 7.55 (d, J = 7.2 Hz, 2H), 7.90 (d, J = 8.2 
Hz, 2H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.4, 35.2, 44.4, 53.1, 58.5, 62.4, 66.5, 74.7, 
125.8, 127.4, 128.3, 128.4, 129.7, 141.8.  LCMS:  RT 0.785 min, m/z = 359.9 [M+H]
+, >99% @ 
215 and 254 nm.  HRMS: C20H25NO3S, Calculated [M+H]
+: 359.1555, Found [M+H]+: 359.1557.  
[α]D20 = +25.1 (c = 0.5, CH3OH). 
 
 
(R)-4-(benzo[d]dioxol-5-ylmethyl)-2-phenethylmorpholine (VU0651732). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.71 (m, 1H), 1.75-1.92 (m, 2H), 2.16 (t, J = 11.0 Hz, 
1H), 2.59-2.83 (m, 4H), 3.41 (s, 2H), 3.51 (bs, 1H), 3.67 (t, J = 11.6 Hz, 1H), 3.85-3.92 (m, 1H), 
5.95 (s, 2H), 6.75 (s, 2H), 6.85 (s, 1H), 7.15-7.21 (m, 3H), 7.24-7.30 (m, 2H).  13C NMR (CDCl3, 
100 MHz) δ (ppm): 31.5, 35.3, 53.0, 58.4, 62.9, 66.6, 74.8, 100.8, 107.8, 109.4, 122.2, 125.7, 
128.3, 128.4, 141.9, 147.6.  LCMS:  RT 0.857 min, m/z = 325.9 [M+H]
+, >99% @ 215 and 254 
nm.  HRMS: C20H23NO3, Calculated [M+H]
+: 325.1678, Found [M+H]+: 325.1683.  [α]D20 = 
+31.3 (c = 0.5, CH3OH). 
 
 
(R)-4-(imidazo[1,2-a]pyridin-2-ylmethyl)-2-phenethylmorpholine (VU0652019). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.87 (m, 2H), 2.02 (t, J = 10.6 Hz, 1H), 2.32 (dt, J = 
3.5, 11.5 Hz, 1H), 2.59-2.82 (m, 2H), 2.82-2.90 (m, 2H), 3.53-3.62 (m, 1H), 3.68-3.78 (m, 3H), 
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3.87-3.93 (m, 1H), 6.76 (dt, J = 1.0, 6.8 Hz, 1H), 7.11-7.19 (m, 4H), 7.22-7.28 (m, 2H), 7.52 (s, 
1H), 7.56 (d, J = 9.1 Hz, 1H), 8.10 (d, J = 6.8 Hz, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
31.5, 35.3, 53.3, 56.7, 58.6, 66.5, 74.7, 111.1, 112.1, 117.4, 124.3, 125.4, 125.7, 128.2, 128.4, 
141.9, 145.1.  LCMS:  RT 0.676 min, m/z = 322.1 [M+H]
+, >99% @ 215 and 254 nm.  HRMS: 
C20H23N3O, Calculated [M+H]
+: 321.1841, Found [M+H]+: 321.1844.  [α]D20 = +27.3 (c = 0.5, 
CH3OH). 
 
 
(R)-4-((1-methyl-1H-indazol-5-ylmethyl)-2-phenethylmorpholine (VU0651730). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.53-1.85 (m, 2H), 1.86-1.99 (m, 1H), 2.14-2.28 (m, 1H), 
2.57-2.81 (m, 4H), 3.45-3.75 (m, 4H), 3.84-3.93 (m, 1H), 4.07 (s, 3H), 7.12-7.19 (m, 3H), 7.22-
7.28 (m, 1H), 7.33-7.44 (m, 2H), 7.61 (s, 1H), 7.93 (s, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
31.5, 35.3, 35.5, 53.1, 58.4, 63.2, 66.5, 74.7, 108.8, 121.2, 123.9, 125.7, 128.0, 128.2, 128.4, 132.5, 
139.4, 141.9.  LCMS:  RT 0.848 min, m/z = 335.9 [M+H]
+, >99% @ 215 and 254 nm.  HRMS: 
C21H25N3O, Calculated [M+H]
+: 335.1998, Found [M+H]+: 335.2002.  [α]D20 = +23.8 (c = 0.333, 
CH3OH, 92% ee). 
 
 
(R)-4-(isoquinolin-6-ylmethyl)-2-phenethylmorpholine (VU0651633).   
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.87 (m, 2H), 1.99 (t, J = 10.6 Hz, 1H), 2.24-2.35 (m, 
1H), 2.58-2.82 (m, 4H), 3.53-3.62 (m, 1H), 3.66-3.79 (m, 3H), 3.87-3.94 (m, 1H), 7.12-7.20 (m, 
3H), 7.22-7.29 (m, 2H), 7.61-7.68 (m, 2H), 7.75 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 8.52 (d, J = 5.7 
Hz, 1H), 9.23 (s, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.4, 35.2, 53.1, 58.4, 63.0, 66.3, 
74.6, 120.3, 125.7, 127.8, 128.1, 128.3 (2C), 128.7, 135.7, 141.8, 143.1, 152.1.  LCMS:  RT 0.668 
min, m/z = 333.2 [M+H]+, >91% @ 215 nm.  HRMS: C22H24N2O, Calculated [M+H]
+: 332.1889, 
Found [M+H]+: 332.1893.  [α]D20 = +30.5 (c = 0.333, CH3OH, 92% ee). 
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(R)-4-(naphthalen-1-ylmethyl)-2-phenethylmorpholine (VU6000124). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.59-1.87 (m, 2H), 1.92-2.05 (m, 1H), 2.20-2.34 (m, 1H), 
2.56-2.66 (m, 1H), 2.66-2.83 (m, 3H), 3.43-3.55 (m, 1H), 3.57-3.72 (m, 1H), 3.82-3.98 (m, 3H), 
7.12-7.19 (m, 3H), 7.22-7.28 (m, 2H), 7.37-7.45 (m, 2H), 7.46-7.56 (m, 2H), 7.75-7.83 (m, 1H), 
7.83-7.94 (m, 1H), 8.28 (d, J = 7.2 Hz, 1H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.6, 35.3, 
53.3, 58.8, 61.5, 66.7, 74.9, 124.7, 125.0, 125.6, 125.7, 128.2, 128.4, 132.5, 133.8.  LCMS:  RT 
0.862 min, m/z = 332.2 [M+H]+, >96% @ 215 and 254 nm.  HRMS: C23H25NO, Calculated 
[M+H]+: 331.1936, Found [M+H]+: 331.1940.  [α]D20 = +48.3 (c = 0.5, CH3OH, 92% ee). 
 
 
(R)-4-(4-chloro-3-fluorobenzyl)-2-phenethylmorpholine (VU6000123). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.60-1.86 (m, 2H), 1.86-1.98 (m, 1H), 2.11-2.30 (m, 1H), 
2.57-2.72 (m, 3H), 2.72-2.84 (m, 1H), 3.36-3.59 (m, 3H), 3.59-3.76 (m, 1H), 3.84-3.94 (m, 1H), 
7.00-7.09 (m, 1H), 7.13-7.21 (m, 4H), 7.23-7.29 (m, 2H), 7.32 (t, J = 7.8 Hz, 1H).  13C NMR 
(CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 53.0, 58.4, 62.0, 66.5, 74.7, 125.2, 125.8, 128.3, 128.4, 
130.3, 141.8, 156.8, 159.2.  LCMS:  RT 0.806 min, m/z = 334.2 [M+H]
+, >99% @ 215 and 254 
nm.  HRMS: C19H21ClFNO, Calculated [M+H]
+: 333.1296, Found [M+H]+: 333.1300.  [α]D20 = 
+30.2 (c = 0.5, CH3OH, 92% ee). 
 
 
(R)-4-(3,4-difluorobenzyl)-2-phenethylmorpholine (VU6000122). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.59-1.86 (m, 2H), 1.86-2.01 (m, 1H), 2.13-2.31 (m, 1H), 
2.57-2.85 (m, 4H), 3.35-3.61 (m, 3H), 3.61-3.82 (m, 1H), 3.85-3.95 (m, 1H), 6.99-7.14 (m, 2H), 
7.14-7.23 (m, 4H), 7.23-7.32 (m, 2H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.5, 35.2, 52.9, 
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58.3, 61.9, 66.3, 74.6, 116.8, 117.0, 117.7, 125.8, 128.3 (2C), 141.8, 148.9, 151.6, 188.6.  LCMS:  
RT 0.749 min, m/z = 318.2 [M+H]
+, >96% @ 215 and 254 nm.  HRMS: C19H21F2NO, Calculated 
[M+H]+: 317.1591, Found [M+H]+: 317.1594.  [α]D20 = +23.4 (c = 0.5, CH3OH, 92% ee). 
 
 
(R)-4-(3,4-dimethylbenzyl)-2-phenethylmorpholine (VU6000121). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.59-1.84 (m, 2H), 1.84-1.94 (m, 1H), 2.11-2.22 (m, 1H), 
2.24 (s, 3H), 2.25 (s, 3H), 2.58-2.84 (m, 4H), 3.43 (s, 2H), 3.47-3.59 (m, 1H), 3.61-3.76 (m, 1H), 
3.82-3.92 (m, 1H), 7.01-7.05 (m, 1H), 7.06-7.10 (m, 2H), 7.14-7.20 (m, 3H), 7.23-7.29 (m, 2H).  
13C NMR (CDCl3, 100 MHz) δ (ppm): 19.3, 19.7, 31.5, 35.3, 53.1, 58.6, 63.0, 66.7, 74.7, 125.7, 
126.7, 128.2, 128.4, 129.4, 130.5, 136.4, 142.0.  LCMS:  RT 0.825 min, m/z = 310.2 [M+H]
+, 
>99% @ 215 and 254 nm.  HRMS: C21H27NO, Calculated [M+H]
+: 309.2093, Found [M+H]+: 
309.2094.  [α]D20 = +29.6 (c = 0.5, CH3OH, 92% ee). 
 
 
(R)-4-((1H-imidazol-2-yl)methyl)-2-phenethylmorpholine (VU0652016). 
LCMS:  RT 0.701 min, m/z = 272.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-4-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)-2-phenethylmorpholine (VU0651665). 
LCMS:  RT 0.889 min, m/z = 336.0 [M+H]
+, >99% @ 215 and 254 nm. 
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2.14 
2-((naphthalen-2-ylmethyl)amino)ethan-1-ol (2.14).  2-(bromomethyl)naphthalene (1.00 g, 4.52 
mmol) was suspended in isopropanol (15.0 mL) in a microwave vial.  To this was added sodium 
hydroxide (181 mg, 4.52 mmol) and 2-aminoethan-1-ol (1.36 mL, 22.6 mmol).  The vial was 
sealed and reacted in the microwave at 120 °C for 10 minutes.  The solution was concentrated and 
purified by column chromatography (5-15% methanol in dichloromethane).  Pure 2.14 was 
recovered as a white solid (766 mg, 84%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 3.76 (t, J = 5.1 Hz, 2H), 3.65 (t, J = 5.1 Hz, 2H), 3.90 (s, 
2H), 7.39-7.51 (m, 3H), 7.71 (s, 1H), 7.76-7.87 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 
50.6, 53.4, 60.5, 125.5, 125.9, 126.3, 126.4, 127.5 (2C), 128.0, 132.5, 133.2, 137.0.   
 
 
2.15 
(S)-(4-(naphthalen-2-ylmethyl)morpholin-2-yl)methanol (2.15).  Aminoalcohol 2.14 (656 mg, 
3.26 mmol) was suspended in water and isopropanol (0.2 M, 1:1 v/v, 16 mL).  (R)-(-)-
Epichlorohydrin (0.27 mL, 3.42 mmol) was added and this was stirred overnight at room 
temperature.  Tetraethylammonium hydroxide (35 wt% in water, 1.6 mL) was added the following 
morning and the reaction was allowed to stir for four hours.  The solution was acidified to pH = 9 
using 2N HCl then extracted with ethyl acetate, dried over sodium sulfate, and concentrated.  
Purification by column chromatography (60-100% ethyl acetate in hexanes) yielded desired 
morpholine 2.15 (426 mg) as well as oxazepane 2.16 (210 mg). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.06 (t, J = 10.7 Hz, 1H), 2.24 (dt, J = 3.3, 8.1 Hz, 1H), 
2.68-2.79 (m, 2H), 3.51-3.78 (m, 6H), 3.87-3.94 (m, 1H), 7.43-7.53 (m, 3H), 7.74 (s, 1H), 7.78-
7.87 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 53.0, 54.5, 63.3, 63.9, 66.4, 76.0, 125.6, 
125.9, 127.2, 127.5, 127.6, 127.7, 127.8, 132.7, 133.1, 134.9.  HRMS: C16H19NO2, Calculated 
[M+H]+: 257.1416, Found [M+H]+: 257.1420.  [α]D20 = +13.3 (c = 1.0, CH3OH).  
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2.16 
(R)-4-(naphthalen-2-ylmethyl)-1,4-oxazepan-6-ol (2.16). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.52-2.62 (m, 1H), 2.83-2.93 (m, 2H), 2.98-3.08 (m, 1H), 
3.67-3.77 (m, 2H), 3.81 (s, 2H), 3.83-3.94 (m, 3H), 7.43-7.54 (m, 3H), 7.72 (s, 1H), 7.77-7.86 (m, 
3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 57.1, 57.8, 63.4, 68.9, 69.9, 76.1, 125.9, 126.2, 126.9, 
127.7, 127.8, 128.4, 132.9, 133.3.  HRMS: C16H19NO2, Calculated [M+H]
+: 257.1416, Found 
[M+H]+: 257.1418.  [α]D20 = +11.4 (c = 0.5, CH3OH). 
 
 
2.17 
(S)-4-(naphthalen-2-ylmethyl)morpholine-2-carbaldehyde (2.17).  In a flame-dried flask under 
argon, suspended alcohol 2.X (600 mg, 2.33 mmol) in anhydrous dichloromethane (23.0 mL).  
Added Dess-Martin Periodinane (1.48 g, 3.50 mmol) and stirred at room temperature overnight.  
This reaction was quenched with saturated, aqueous sodium bicarbonate and extracted with 
dichloromethane.  After being dried over sodium sulfate and concentrated, the product was purified 
by column chromatography (30-80% ethyl acetate in hexanes).  This gave pure aldehyde 2.17 (320 
mg, 61%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.25-2.32 (m, 1H), 2.32-2.40 (m, 1H), 2.65-2.72 (m, 1H), 
2.90-2.98 (m, 1H), 3.70 (s, 2H), 3.74-3.83 (m, 1H), 3.98 (dt, J = 3.3, 11.5 Hz, 1H), 4.06-4.12 (m, 
1H), 7.42-7.51 (m, 3H), 7.71 (s, 1H), 7.77-7.85 (m, 3H), 9.62 (s, 1H).   
 
 
2.18 
(R)-2-ethynyl-4-(naphthalen-2-ylmethyl)morpholine (2.18).  In a flame-dried flask under 
argon, added aldehyde 2.17 (250 mg, 0.979 mmol) in anhydrous methanol (16.0 mL).  Added to 
this was potassium carbonate (271 mg, 1.96 mmol) and dimethyl (1-diazo-2-
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oxopropyl)phosphonate (226 mg, 1.18 mmol).  This reaction was stirred at room temperature 
overnight.  In the morning, the mixture was diluted with water, extracted with ethyl acetate, dried 
over sodium sulfate, and concentrated in vacuo.  After purification by column chromatography (0-
50% ethyl acetate in hexanes), pure alkyne 2.18 was recovered (115 mg, 47%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.35-2.45 (m, 2H), 2.45-2.49 (m, 1H), 2.59-2.66 (m, 1H), 
2.80-2.87 (m, 1H), 3.64-3.74 (m, 3H), 3.96 (dt, J = 3.3, 11.4 Hz, 1H), 4.35-4.42 (m, 1H), 7.44-
7.54 (m, 3H), 7.76 (s, 1H), 7.80-7.88 (m, 3H).   
 
General procedure for Sonogashira couplings and hydrogenations: 
Alkyne 2.18 (15.0 mg, 0.060 mmol) was suspended in triethylamine (0.5 mL) in a microwave vial.  
The desired aryl iodide or aryl bromide (0.072 mmol) was added along with copper (I) iodide 
(0.006 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.003 mmol).  The microwave vial 
was sealed, purged with argon, and reacted in the microwave at 120 °C for 10 minutes.  Product 
formation was confirmed by LCMS and the reaction mixture was diluted in dichloromethane and 
extracted from water.  Purification was done by automated reverse phase column chromatography.  
These products were suspended in methanol and stirred under hydrogen with 10% palladium on 
carbon until the alkyne was reduced.  Purification of these final compounds was done by automated 
reverse phase column chromatography.   
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-(2-(trifluoromethoxy)phenethyl)morpholine (VU6000119). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.59-1.84 (m, 2H), 1.90-2.02 (m, 1H), 2.17-2.33 (m, 1H), 
2.64-2.89 (m, 4H), 3.52 (bs, 1H), 3.59-3.76 (m, 3H), 3.83-3.94 (m, 1H), 7.14-7.21 (m, 3H), 7.21-
7.25 (m, 1H), 7.42-7.53 (m, 3H), 7.73 (s, 1H), 7.77-7.86 (m, 3H).  13C NMR (CDCl3, 100 MHz) 
δ (ppm): 25.7, 33.6, 53.1, 58.6, 63.4, 66.6, 74.7, 120.3, 125.6, 125.9, 126.6, 127.2, 127.3, 127.6 
(2C), 127.7, 127.9, 130.8, 132.8, 133.2, 134.3, 147.6.  LCMS:  RT 1.025 min, m/z = 415.9 [M+H]
+, 
>99% @ 215 and 254 nm.   
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(R)-2-(2-(6-fluoropyridin-2-yl)ethyl)-4-(naphthalen-2-ylmethyl)morpholine (VU0657026). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.80-1.89 (m, 2H), 1.90-2.03 (m, 1H), 2.16-2.30 (m, 1H), 
2.65-2.93 (m, 4H), 3.53 (bs, 1H), 3.59-3.77 (m, 3H), 3.83-3.91 (m, 1H), 6.69 (dd, J = 2.8, 8.2 H, 
1H), 6.99 (dd, J = 2.4, 7.2 Hz, 1H), 7.42-7.52 (m, 3H), 7.62 (q, J = 8.2 Hz, 1H), 7.72 (s, 1H), 7.78-
7.85 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 32.8, 33.1, 53.1, 58.5, 63.3, 66.5, 74.7, 
106.2, 106.6, 119.9, 120.0, 125.7, 126.0, 127.3, 127.6, 127.7, 127.9, 132.8, 133.2, 141.0, 141.1, 
160.8, 160.9, 161.9, 164.3.  LCMS:  RT 0.882 min, m/z = 351.0 [M+H]
+, >99% @ 215 and 254 
nm.   
 
 
(R)-3-(2-(4-(naphthalen-2-ylmethyl)morpholin-2-yl)ethyl)benzonitrile (VU0657025). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.56-1.85 (m, 2H), 1.94 (t, J = 10.3 Hz, 1H), 2.18-2.32 (m, 
1H), 2.61-2.85 (m, 4H), 3.45 (bs, 1H), 3.56-3.77 (m, 3H), 3.84-3.93 (m, 1H), 7.30-7.40 (m, 2H), 
7.42-7.53 (m, 5H), 7.73 (s, 1H), 7.78-7.87 (m, 3H).  13C NMR (CDCl3, 100 MHz) δ (ppm): 31.1, 
34.7, 53.2, 58.4, 63.3, 66.6, 74.3, 112.3, 118.9, 125.7, 126.0, 127.3, 127.6 (2C), 128.0, 129.0, 
129.6, 131.9, 132.8, 133.0, 133.2, 143.3.  LCMS:  RT 0.948 min, m/z = 356.9 [M+H]
+, >99% @ 
215 and 254 nm.  HRMS: C24H24N2O, Calculated [M+H]
+: 356.1889, Found [M+H]+: 356.1893. 
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-(2-(pyridin-3-yl)ethyl)morpholine (VU0657080). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.58-1.85 (m, 2H), 1.93-2.04 (m, 1H), 2.22-2.36 (m, 1H), 
2.59-2.70 (m, 1H), 2.71-2.87 (m, 3H), 3.57 (bs, 1H), 3.63-3.83 (m, 3H), 3.86-3.95 (m, 1H), 7.17 
(dd, J = 4.8, 7.7 H, 1H), 7.43-7.54 (m, 4H), 7.75 (s, 1H), 7.78-7.87 (m, 3H), 8.38-8.48 (m, 2H).  
13C NMR (CDCl3, 100 MHz) δ (ppm): 28.6, 34.8, 53.0, 58.3, 63.2, 66.4, 74.2, 123.2, 125.8, 126.1, 
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127.3, 127.6, 127.7, 128.1, 132.8, 133.2, 135.8, 147.3, 149.9.  LCMS:  RT 0.672 min, m/z = 332.9 
[M+H]+, >99% @ 215 and 254 nm.  HRMS: C22H24N2O, Calculated [M+H]
+: 332.1889, Found 
[M+H]+: 332.1894. 
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-(2-(pyridin-2-yl)ethyl)morpholine (VU0657082). 
LCMS:  RT 0.664 min, m/z = 333.0 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-2-(2-(2-fluoropyridin-3-yl)ethyl)-4-(naphthalen-2-ylmethyl)morpholine (VU0657071). 
LCMS:  RT 0.895 min, m/z = 350.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-2-(2-(4-(naphthalen-2-ylmethyl)morpholin-2-yl)ethyl)benzonitrile (VU6000128). 
LCMS:  RT 0.932 min, m/z = 356.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-(4-(trifluoromethoxy)phenethyl)morpholine (VU6000127). 
LCMS:  RT 1.046 min, m/z = 415.9 [M+H]
+, >99% @ 215 and 254 nm. 
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(R)-4-(naphthalen-2-ylmethyl)-2-(2-(trifluoromethyl)phenethyl)morpholine (VU6000126). 
LCMS:  RT 1.075 min, m/z = 399.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-2-(2-methoxyphenethyl)-4-(naphthalen-2-ylmethyl)morpholine (VU6000125). 
LCMS:  RT 1.001 min, m/z = 361.9 [M+H]
+, >99% @ 215 and 254 nm. 
 
 
(R)-4-(naphthalen-2-ylmethyl)-2-(2-(thizol-2-yl)ethyl)morpholine (VU6000120). 
LCMS:  RT 0.880 min, m/z = 338.9 [M+H]
+, >99% @ 215 and 254 nm.  
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